Escape of human solid tumors from t-cell recognition: molecular mechanisms and functional significance

Advances in Immunology

Volumn , Issue 74, 2000, Pages 181-273

  Marincola, Francesco M ^a,d   Jaffee, Elizabeth M ^a,b   Hickljn, Daniel J ^a,b,c   Ferrone, Soldano ^a,b,c  

^a NATIONAL CANCER INSTITUTE   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c ELI LILLY AND COMPANY   (United States)

^d ROSWELL PARK CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

TUMOR ANTIGEN;

HUMAN; IMMUNOSURVEILLANCE; PRIORITY JOURNAL; REVIEW; SOLID TUMOR; T LYMPHOCYTE; TARGET CELL; TUMOR IMMUNOLOGY;

AMINO ACID SEQUENCE; ANIMALS; ANTIGEN PRESENTATION; ANTIGENS, NEOPLASM; APOPTOSIS; CYTOKINES; DISEASE PROGRESSION; EPITOPES; GENE EXPRESSION REGULATION, NEOPLASTIC; HLA ANTIGENS; HUMANS; IMMUNE TOLERANCE; IMMUNODOMINANT EPITOPES; IMMUNOLOGIC SURVEILLANCE; IMMUNOTHERAPY; LYMPHOCYTE ACTIVATION; MELANOMA, EXPERIMENTAL; MICE; MODELS, IMMUNOLOGICAL; NEOPLASM METASTASIS; NEOPLASMS; POLYMORPHISM, GENETIC; T-LYMPHOCYTES, CYTOTOXIC; T-LYMPHOCYTES, HELPER-INDUCER;

EID: 0033991158     PISSN: 00652776     EISSN: None     Source Type: Book Series    
DOI: None     Document Type: Article

References (445)

1. Abken, H., Hombach, A., Reinhold, U., and Ferrone, S. (1998). Can combined T-cell- and antibody-based immunotherapy outsmart tumor cells? Immunol. Todaij 19, 2-5.
2. Akella, R., and Hall, R. E. (1992). Expression of the adhesion molecules ICAM-1 and ICAM-2 on tumor cell lines does not correlate with their susceptibility to natural killer cell-mediated cytolysis: evidence for additional ligands for effector cell beta integrins. Eur. ]. Immunol. 22, 1069-1074.
3. Akporiaye, E. T., and Panelli, M. C. (1996). Functional class II antigen presentation pathway in metastatic melanoma cell lines. J. Immunother. 19, 398.
4. Albert, M. L., Sauter, B., and Bhardwaj, N. (1998). Dendritic cells acquire antigen from apoptotic cells and induce class I-restricted CTLs. Nature 392, 86-89.
5. Albino, A. P., Lloyd, K. O., Houghton, A. N., Oettgen, H. F., and Old, L. J. (1981). Heterogeneity in surface antigen and glycoprotein expression of cell lines derived from different melanoma métastases of the same patient. Implications for the study of tumor antigens. J. Exp. Med. 154, 1764-1778.
6. Alexander-Miller, M. A., Leggatt, G. R., Sarin, A. and Berzofsky, J. A. (1996). Role of antigen, CDS, and cytotoxic T lymphocyte (CTL) avidity in high dose antigen induction of apoptosis of effector CTL. J. Exp. Med. 184, 485-492.
7. Allan, D. S., Colonna, M., Lanier, L. L., Churakova, T. D., Abrams, J. S., and Ellis, S. A. (1999). Tetrameric complexes of HLA-G bind to peripheral blood myclomonocytic cells. J. Exp. Med. 189(7):1149-1156.
8. Alpan, R. S., Zhang, M., and Pardee, A. B. (1996). Cell cycle-dependent expression of TAPI, TAP2, and HLA-B27 messenger RNAs in a human breast cancer cell line. Cancer Res. 56, 4358-4361.
9. Altman, J. D., Moss, P. II., Goulder, P. R., Barouch, D. IL, McHeyzer-Williams, M. G., Bell, J. I., McMichael, A. J., and Davis, M. M. (1996). Phenotypic analysis of antigenspecific T lymphocytes [published erratum, Science 1998; 280(5371):1821].
10. Science 274, 94-96.
11. Altomonte, M., Gloghini, A., Bertola, G., Gasparollo, Carbone, A., and Ferrone, S. (1993). Differential expression of cell adhesion molecules CD54/CDlla and CD58/CD2 by human melanoma cells and functional role in their interaction with cytotoxic cells. Cancer Res. 53, 3343-3348.
12. Arai, IL, Gordon, D., Nabel, E. G., and Nabel, G. J. (1997). Gene transfer of Fas ligand induces tumor regression in vivo. Proc. Natl. Acad. Sci. USA 94, 13862-13S67.
13. Armstrong, T. D., Clements, V. K., and Ostrand-Rosenberg, S. (1998). MIIC class IItransfected tumor cells directly present antigen to tumor-specific CD4+ T lymphocytes. J. Immunol. 160, 661-666.
14. Baliler, D. W., Frelinger, J. G., Harwell, L. W., and Lord, E. M. (1987). Reduced tumorigenicity of a spontaneous mouse lung carcinoma following H-2 gene transfection. Proc. Natl. Acad. Sci. USA 84, 4562-4566.
15. Bander, N. IL, Yao, D., Liu, IL, Chen, Y. T., Steiner, M., Zuccaro, W., and Moy, P. (1997). MIIC class I and II expression in prostate carcinoma and modulation by intcrferon-alpha and -gamma. Prostate 33, 233-239.
16. Becker, J. C., Dummer, R., Hartmann, A. A., Burg, G., and Schmidt, R. E. (1991). Shedding of ICAM-1 from human melanoma cell lines induced by IFN-gamma and tumor necrosis factor-alpha. Functional consequences on cell-mediated cytotoxicity. J. Immunol. 147, 4398-4401.
17. Bedford, M. T., and van Helden, P. D. (1987). Hypomethylation of DNA in pathological conditions of the human prostate. Cancer Res. 47, 5274-5276.
18. Bellone, G., Aste-Amezaga, M., Trinchieri, G., and Rodeck, U. (1995) Regulation of NK cell functions by TGF-beta l. J. Immunol. 155, 1066-1073.
19. Benitez, R., Godelaine, D., Lopez-Nevot, M. A., Brausseur, F., Jimenez, P., Marchand, M., Oliva, M. R., vanBaren, N., Cabrera, T., Andry, G., Landry, G., Ruiz-Cabello, F., Boon, T., and Garrido, F. (1998). Mutations of the /32-microgIobulin gene result in a lack of HLA class I molecules on melanoma cells of two patients immunized with MAGE peptides. Tissue Antigens 52, 520-529.
20. Bennett, M. W., O'Connell, J., O'Sullivan, G. C., Brady, C., Röche, D., Collins, J. K., and Shanahan, F. (1998). The Fas counterattack in vivo: Apoptotic depletion of tumorinfiltrating lymphocytes associated with Fas ligand expression by human esophageal carcinoma. J. Immunol. 160, 5669-5675.
21. Bernards, R., Dessain, S. K., and Weinberg, R. A. (19S6). N-myc amplification causes downmodulation of MIIC class I antigen expression in neuroblastoma. Cell 47, 667-674.
22. Bettinotti, M., Kirn, C. J., Lee, K.-IL, Roden, M., Cormier, J. N., Panelli, M. C., Parker, K. C., and Marincola, F. M. (1998). Stringent allele/epitope requirements for MART-1/ Melan A immunodominance: implications for peptide-based immunotherapy.J. Immunol. 161, 877-889.
23. Bevan, M. J. (1997). In thymic selection, peptide diversity gives and takes away. Immunity. 7, 175-178.
24. Bhardwaj, N., Bender, A., Gonzalez, N., Bui, L. K., Garrett, M. C., and Steinman, R. M. (1994). Influenza virus-infected dendritic cells stimulate strong proliferative and cytolytic responses from human CD8+ T cells.J. Clin. Invest. 94, 797-807.
25. Bicknell, D. C., Kaklamanis, L., Hampson, R., Bodmer, W. F., and Karran, P. (1996). Selection for beta 2-microglobulin mutation in mismatch repair-defective colorectal carcinomas. Cuir. Biol 6, 1695-1697.
26. Bicknell, D, C., Rowan, A., and Bodmer, W. F. (1994). Beta 2-microglobulin gene mutations: A study of established colorectal cell lines and fresh tumors. Proc. Natl. Acacl. Sci. USA 91, 4751-4756.
27. Biddison, W. E., and Palmer, J. C. (1977). Development of tumor cell resistance to syngeneic cell-mediated cytotoxicity during growth of ascitic mastocytoma P815Y. Proc. Natl. Acad. Sci. USA 74, 329-333.
28. Bjorkman, P. J., Saper, M. A., Samraoui, B., Bennett, W. S., Strominger, J. L., and Wiley, D. C. (1987). Structure of the human class I histocompatibility antigen, IILA-A2. Nature 329, 506-512.
29. Blades, R. A., Keating, P. J., McWilliam, L. J., George, N. J., and Stern, P. L. (1995). Loss of HLA class I expression in prostate cancer: Implications for immunotherapy. Urology. 46, 681-686.
30. Blanchet, O., Bourge, J. F., Zinszer, II., Talari, Z., Degos, L., and Paul, P. (1991). Int. J. Cancer Sitppl. 6, 138-145.
31. Blanchet, O., Bourge, J. F., Zinszner, H., Israel, A., Kourilsky, P., Dausset, J., Degos, L., and Paul, P. (1992). Altered binding of regulatory factors to HLA class I enhancer sequence in human tumor cell lines lacking class I antigen expression. Proc. Natl. Acad. Sci. USA 89, 3488-3492.
32. Boel, P., Wildmann, C., Sensi, M. L., Brasseur, R., Renauld, J. C., Coulie, P., Boon, T., and van der Bruggen, P. (1995). BAGE: A new gene encoding an antigen recognized on human melanomas by cytolytic T lymphocytes. Immunity 2, 167-175.
33. Bonner, R. F., Emmert-Buck, M., Cole, K., Pohida, T., Chuaqui, R., Goldstein, S., and Uotta, L. A. (1997). Laser capture microdissection: Molecular analysis of tissue. Science 278, 1481-1483.
34. Boon, T., Coulie, P. G., and Van den Eynde, B. (1997). Tumor antigens recognized by T cells. Immunol. Today 18, 267-268.
35. Boon, T., De Plaen, E., Lurquin, C., Van den Eynde, B., van der Bruggen, P., Traversari, C., Amar-Costesec, A., and Van Pel, A. (1992). Identification of tumour rejection antigens recognized by T lymphocytes. Cancer Surv. 3, 23-37.
36. Bortin, M. M., and Truitt, R. L. (1980). Proc. first international symposium on alien histocompatibility antigens on cancer cells. Transplant Proc. 12, 1-215.
37. Bortin, M. M., and Truitt, R. L. (1981). Proc. second international symposium on alien histocompatibility antigens on cancer cells. Transplant Proc. 13, 1751-2001.
38. Brady, M. S., Eckels, D. D., Ree, S. Y., Schultheiss, K. E., and Lee, J. S. (1996). MHC class II-mediated antigen presentation by melanoma cells. J. Immunother. 19, 387-397.
39. Braendstrup, O., Jensen, L., and Werdelin, O. (1996). Sertoli cells, but not tumor cells, of seminoma in situ express ICAM-1. APA//S 104, 817-822.
40. Brakenhoff, J. P. J. (1995). Interleukin-6 receptor antagonists. Dig. Neural. Psych. 8, 397-403.
41. Branch, P., Bicknell, D. C., Rowan, A., Bodmer, W. F., and Karran, P. (1995). Immune surveillance in colorectal carcinoma. Nat Genet. 9, 231-232.
42. Brandie, D., Brasseur, F., Weynants, P., Boon, T., and Van den Eynde, B. (1996). A mutated HLA-A2 molecule recognized by autologous cytotoxic T lymphocytes on a human renal cell carcinoma. J. Exp. Med. 183, 2501-2508.
43. Braud, V., Jones, E. Y., and McMichael, A. (1997). The human major histocompatibility complex class Ib molecule HLA-E binds signal sequence-derived peptides with primary anchor residues at positions 2 and 9. Eiir. ]. Immunol. 27, 1164-1169.
44. Braud, V. M., Allan, D. S., O'Callaghan, C. A., Soderstrom, K., D'Andréa, A., Ogg, G. S., Lazetic, S., Young, N. T., Bell, J. I., Phillips, J. H., Lanier, L. L., and McMichael, A. J. (1998). HLA-E binds to natural killer cell receptors CD94/NKG2A, B and C. Nature 391, 795-799.
45. Brichard, V., Van Pel, A., Wolfel, T., Wolfel, C., De Plaen, E., Lethe, B., Coulie, P. and Boon, T. (1993). The tyrosinase gene codes for an antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas. J. Exp. Med. 178, 489-495.
46. Brichard, V. G., Herman, J., Van Pel, A., Wildmann, C., Gaugler, B., Wolfel, T., Boon, T., and Lethe, B. (1996). A tyrosinase nonapeptide presented by HLA-B44 is recognized on a human melanoma by autologous cytolytic T lymphocytes. Eur. J. Immunol. 26, 224-230.
47. Brocker, E. B., Suter, L., Bruggen, J., Ruiter, D. J., Macher, E., and Sorg, C. (1985). Phenotypic dynamics of tumor progression in human malignant melanoma. Int. J. Cancer 36, 29-35.
48. Brocker, E. B., Suter, L., and Sorg, C. (1984). HLA-DR antigen expression in primary melanomas of the skin.J. Invest. Dennatol. 82, 244-247.
49. Bromvenstijn, N., Slager, E. H., Bakker, A. B., Schreurs, M. W., Van der Spek, C. W., Adema, G. J., Schrier, P. I., and Figdor, C. G. (1997). Transcription of the gene encoding melanoma-associated antigen gplOO in tissues and cell lines other than those of the melanocytic lineage. Br. ]. Cancer 76, 1562-1566.
50. Brower, R. C., England, R., Takeshita, T., Kozlowsto, S., Margulies, D. H., Berzofsky, J. A., and Delisi, C. (1994). Minimal requirements for peptide mediated activation of CD8+ CTL. Mol. Immunol. 31, 1285-1293.
51. Browning, M. J., Krausa, P., Rowan, A., Bicknell, D. C., Bodmer, J. G., and Bodmer, W. F. (1993). Tissue typing the IILA-A locus from genomic DNA by sequence-specific PCR: comparison of HLA genotype and surface expression on colorectal tumor cell lines. Troc. Natl. Acad. Sci. USA 90, 2842-2845.
52. Budinsky, A. C., Brodowicz, T., Wiltschke, C., Czerwenka, K., Michl, I., Krainer, M., and Zielinski, C. C. (1997). Decreased expression of ICAM-1 and its induction by tumor necrosis factor on breast-cancer cells in vitro. Int. J. Cancer 71, 10S6-1090.
53. Burchiel, S. W., Martin, ]. C., Imai, K., Ferrone, S., andWamer, N. L. (1982). Heterogeneity of HLA-A, B, la-like, and melanoma-associated antigen expression by human melanoma cell lines analyzed with monoclonal antibodies and flow cytometry. Cancer Res. 42, 4110-4115.
54. Burnet, F. M. (1970). The concept of immunological surveillance. Prog. Exp. Tumor Res. 13, 1-27.
55. Busam, K. J., Chen, Y. T., Old, L. J., Stockert, E., Iversen, K., Coplan, K. A., Rosai, J., Barnhill, R. L., and Jungbluth, A. A. (1998a). Expression of melan-A (MARTI) in benign melanocytic nevi and primary cutaneous malignant melanoma. Am. J. Surg. Pathol. 22, 976-982.
56. Busam, K. J., Iversen, K., Coplan, K. A., Old, L. J., Stockert, E., Chen, Y. T., McGregor, D., and Jungbluth, A. (1998b). Immunoreactivity for A103, an antibody to melan-A (Mart1), in adrenocortical and other steroid tumors. Am. J. Surg. Pathol. 22, 57-63.
57. Buszello, H., and Ackermann, R. (1992). Expression of HLA class-I antigens on renal cell carcinoma and non-transformed renal tissue. Eur. Ural. 21, 70-74.
58. Buszello, H., and Ackermann, R. (1994). Immunohistochemical studies on the expression of HLA class I antigens in renal cell carcinoma: Comparison of primary and metastatic tumor tissue. Enr. Urol. 25, 158-163.
59. Cabrera, T., Angustias, F. M., Sierra, A., Garrido, A., Herruzo, A., Escobedo, A., Fabra, A., and Garrido, F. (1996). High frequency of altered HLA class I phenotypes in invasive breast carcinomas. Hum. Immunol. 50, 127-134.
60. Cabrera, T., Collado, A., Fernandez, M. A., Ferron, A., Sancho, J., Ruiz-Cabello, F., and Garrido, F. (1998). High frequency of altered HLA class I phenotypes in invasive colorectal carcinomas. Tissue Antigens 52, 114-123.
61. Cabrera, T., Concha, A., Ruiz-Cabello, F., and Garrido, F. (1991). Loss of HLA heavy chain and beta 2-microglobulin in HLA negative tumours. Scand.J. Immunol. 34, 147-152.
62. Cao, X., Chen, G., He, L., Zhang, W., Yu, Y., and Wang, J. (1997). Involvement of MHC class I molecule and ICAM-1 in the enhancement of adhesion and cytotoxic susceptibility to immune effector cells of tumor cells transfected with the interleukin (IL)-2, IL-4 or IL-6 gene. J. Cancer. Res. Clin. Oncol. 123, 602-608.
63. Carbone, F. R., Moore, M. W., Sheil, J. M., and Bevan, M. J. (1988). Induction of cytotoxic T lymphocytes by primary in vitro Stimulation with peptides.J. Exp. Med. 167, 1767-1779.
64. Cardi, G., Heaney, J. A., Schned, A. R., and Emstoff, M. S. (1998). Expression of Fas(APO-1/CD95) in tumor-infiltrating and peripheral blood lymphocytes in patients with renal cell carcinoma. Cancer Res. 58, 2078-2080.
65. Castelli, C., Storkus, W. J., Maeurer, M. J., Martin, D. M., Huang, E. C., Pramanik, B. N., Nagabhushan, T. L., Parmiani, G., and Lotze, M. T. (1995). Mass spectrometric identification of a naturally processed melanoma peptide recognized by CD8+ cytotoxic T lymphocytes.J. Exp. Med. 181, 363-368.
66. Chappell, D. B., Zaks, T. Z., Rosenberg, S. A., and Restifo, N. P. (1999). Human melanoma cells do not express Fas (Apo-l/Cd95) ligand. Cancer Res. 59, 59-62.
67. Chen, H. L., Gabrilovich, D., Tampe, R., Girgis, K. R., Nadaf, S., and Carbone, D. P. (1996). A functionally defective allele of TAPI results in loss of MHC class I antigen presentation in a human lung cancer. Nat. Genet. 13, 210-213.
68. Chen, Y.-T., Stockert, E., Tsang, S., Coplan, K. E., and Old, L. J. (1995). Immunophenotyping of melanomas for tyrosinase: implications for vaccine development. Proc. Natl. Acad. Sci. USA 92, 8125-8129.
69. Chen, Y., Sidney, J., Southwood, S., Cox, A. L., Sakaguchi, K., Henderson, R. A., Appella, E., Hunt, D. F., Seite, A., and Engelhard, V. H. (1994). Naturally processed peptides longer than nine amino acid residues bind to the class I MHC molecule HLA-A2.1 with high affinity and in different conformations. J. Immunol. 152, 2874-2881.
70. Chouaib, S., Asselin-Paturel, C., Mami-Chouaib, F., Caignard, A., and Blay, J. Y. (1997). The host-tumor immune conflict: From immunosuppression to resistance and destruction. Immunol. Today 18, 493-497.
71. Christinck, E. R., Luscher, M. A., Barber, B. H., and Williams, D. B. (1991). Peptide binding to class I MHC on living cells and quantitation of complexes required for CTL lysis. Nature 352, 67-70.
72. Cikes, M. (1971). Variations in expression of surface antigens on cultured cells. Ann. NY Acad. Sci. 177, 190-200.
73. Cikes, M., and Friberg, S. J. (1971). Expression of H-2 and Moloney leukemia virusdetermined cell-surface antigens in synchronized cultures of a mouse cell line. Proc. Natl. Acad. Sci. USA 68, 566-569.
74. Cikes, M., Friberg, S. J., and Klein, G. (1973). Progressive loss of H-2 antigens with concomitant increase of cell-surface antigen(s) determined by Moloney leukemia virus in cultured murine lympbomas. J. Natl. Cancer Inst. 50, 347-362.
75. Cillo, C., Mach, J. P., Schreyer, M., and Carrel, S. (1984). Antigenic heterogeneity of clones and subclones from human melanoma cell lines demonstrated by a panel of monoclonal antibodies and flow microfluorometry analysis. Int. J. Cancer 34, 11-20.
76. Clerici, M., and Shearer, G. M. (1994). The Thl-Th2 hypothesis of HIV infection: new insights. Immunol. Today 15, 575-581.
77. Concha, A., Cabrera, T., Ruiz-Cabello, F., and Garrido, F. (1991). Can the IILA phenotype be used as a prognostic factor in breast carcinomas? Int. J. Cancer Suppl. 6, 146-154.
78. Connor, M. E., and Stem, P. L. (1990). Loss of MHC class-I expression in conical carcinomas. Int. J. Cancer 46, 1029-1034.
79. Coral, S., Sigaloti, L., Gasparollo, A., Cattarossi, I., Visintin, A., Cattelan, A., Altomonte, M., and Maio, M. (1999). Prolonged upregulation of the expression of HLA class I antigens and costimulatory molecules on melanoma cells treated with 5-aza-2'-deoxycytidine (5-AZA-CdR). J. Immunother. 22, 16-24.
80. Cordon-Cardo, G., Fuks, Z., Drobnjak, M., Moreno, C., Eisenbach, L., and Feldman, M. (1991). Expression of HLA-A, B, C antigens on primary and metastatic tumor cell populations of human carcinomas. Cancer Res. 51, 6372-6380.
81. Cormier, J. N., Abati, A., Fetsch, P., Hijazi, Y. M., Rosenberg, S. A., Marihcola, F. M., and Topalian, S. L. (1998a). Comparative analysis of the in vivo expression of tyrosinase, MART-1/Melan-A, and gp100 in metastatic melanoma lesions: implications for immunotherapy. J. Immunother. 21, 27-31.
82. Cormier, J. N., Hijazi, Y. M., Abati, A., Fetsch, P., Bettinotti, M., Steinberg, S. M., Rosenberg, S. A., and Marincola, F. M. (1998b). Heterogeneous expression of melanoma-associated antigens (MAA) and HLA-A2 in metastatic melanoma i;i vivo. Int. J. Cancer 75, 517-524.
83. Cormier, J. N., Panelli, M. C., Hackett, J. A., Bettinotti, M., Mixon, A., Wunderlich, J., Parker, L., Restifo, N. P., Ferrone, S., and Marincola, F. M. (1999). Natural variation of the expression of HLA and endogenous antigen modulates CTL recognition in an in vitro melanoma model. Int. J. Cancer 80, 781-790.
84. Cormier, J. N., Salgaller, M. L., Prevette, T., Barracchini, K. C., Rivoltini, L., Restifo, N. P., Rosenberg, S. A., and Marincola, F. M. (1997). Enhancement of cellular immunity in melanoma patients immunized with a peptide from MART-l/Melan A. Cancer J. Sci. Am. 3, 37-44.
85. Coulie, P. G., Brichard, V., Van Pel, A., Wolfel, T., Schneider, J., Traversari, C., Mattei, S., De Plaen, E., Lurquin, C., Szikora, J. P. and Boow T. (1994). A new gene coding for a differentiation antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas. J. Exp. Med. 180, 35-42.
86. Coulie, P. G., Lehmann, F., Lethe, B., Herman, J., Lurquin, C., Andrawiss, M., and Boon, T. (1995). A mutated intron sequence codes for an antigenic peptide recognized by cytolytic T lymphocytes on a human melanoma. Proc. Natl. Acad. Sci. USA 92, 7976-7980.
87. Cox, A. L., Skipper, J., Chen, Y., Henderson, R. A., Darrovv, T. L., Shabanowitz, J., Engelhard, V. IL, Hunt, D. F., and Slingluff, C. L., Jr. (1994). Identification of a peptide recognized by five melanoma-specific human cytotoxic T cell lines. Science 264, 716-719.
88. Cromme, F. V., Meijer, C. J., Snijders, P. J., Uyterlinde, A., Kenemans, P., Helmerhorst, T., Stern, P. L., van den Brule, A. J., and Walboomers, J. M. (1993a). Analysis of MHC class I and II expression in relation to presence of HPV genotypes in premalignant and malignant cervical lesions. Br. J. Cancer 67, 1372-1380.
89. Cromme, F. V., Snijders, P. J., van den Brule, A. J., Kenemans, P., Meijer, C. J., and Walboomers, J. M. (1993b). MHC class I expression in HPV 16 positive cervical carcinomas is post-transcriptionally controlled and independent from c-myc overexpression. Oncogcne 8, 2969-2975.
90. Cromme, F. V., Airey, J., Heemels, M. T., Ploegh, H. L., Keating, P. J., Stem, P. L., Meijer, C. J., and Walboomers, J. M. (1994a). Loss of transporter protein, encoded by the TAP-1 gene, is highly correlated with loss of H LA expression in cervical carcinomas. J. Exp. Mod. 179, 335-340.
91. Cromme, F. V., van Bommel, P. F., Walboomers, J. M., Gallee, M. P., Stem, P. L., Kenemans, P., Heimerhorst, T. J., Stukart, M. J., and Meijer, C. J. (1994b). Differences in MHC and TAP-1 expression in cervical cancer lymph node métastases as compared with the primary tumours. Br. ]. Cancer 69, 1176-1181.
92. Crow-ley, N. J., Darrow, T. L., Quinn-Allen, M. A., and Seigier, H. F. (1991). MHC-restricted recognition of autologous melanoma by tumor-specific cytotoxic T cells. Evidence for restriction by a dominant HLA-A allele. J. Immunol. 146, 1692-1699.
93. D'Alessandro, G., Zardawi, L, Grace, J., McCarthy, W. H., and Hersey, P. (1987). Immunohistological evaluation of MHC class I and II antigen expression on nevi and melanoma: Relation to biology of melanoma. Pathology 19, 339-346.
94. De Baetselier, P., Katzav, S., Gorelik, E., Feldman, M., and Segal, S. (19SO). Differential expression of H-2 gene products in tumour cells in associated with their metastatogenic properties. Nature 288, 179-181.
95. De Smet, C., De Backer, O., Faraoni, L, Lurquin, C., Brasseur, F., and Boon, T. (1996). The activation of human gene MAGE-1 in tumor cells is correlated with genome-wide demethylation. Proc. Natl. Acad. Sci. USA 93, 7149-7153.
96. de Vries, T. J., Fourkour, A., Wobbes, T., Verkroost, G., Ruiter, D. J., and van Muijen, G. N. (1997). Heterogeneous expression of immunotherapy candidate proteins gplOO, MART-1, and tyrosinase in human melanoma cell lines and in human melanocytic lesions. Cancer Res. 57, 3223-3229.
97. del Guercio, M. F., Sidney, J., Hermanson, G., Ferez, C., Grey, H. M., Kubo, R. T., and Sette, A. (1995). Binding of a peptide antigen to multiple HLA alleles allows definition of an A2-like supertype. J. Immunol. 154, 685-693.
98. Devitt, A., Moffatt, O. D., Raykundalia, C., Capra, J. D., Simmons, D. L., and Gregory, C. D. (1998). Human CD14 mediates recognition and phogocytosis of apoptotic cells. Nature 392, 505-509.
99. D'Orazio, T. J., and Niederkorn, J. Y. (1998). A novel role for TGF-beta and IL-10 in the induction of immune privilege. J. Immunol. 160, 2089-2098.
100. Doyle, A., Martin, W. J., Funa, K., Gazdar, A., Camey, D., Martin, S. E., Linnoila, L, Cuttitta, F., Mulshine, J., and Bunn, P. (1985). Markedly decreased expression of class I histocompatibility antigens, protein, and mRNA in human small-cell lung cancer. J. Exp. Ued. 161, 1135-1151.
101. D'Souza, S., Rimoldi, D., Lienard, D., Lejeune, F., Cerottini, J. C., and Romero, P. (1998). Circulating Melan-A/Mart-1 specific cytolytic T lymphocyte precursors in HLA-A2+ melanoma patients have a memory phenotype. Inf. J. Cancer 78, 699-706.
102. Dudley, M. E., and Roopenian, D. C. (1996). Loss of a unique tumor antigen by cytotoxic T lymphocyte immunoselection from a 3-methylcholanthrene-induced mouse sarcoma reveals secondary unique and shared antigens. J. Exp. Med. 184, 441-447.
103. Duggan, D. J., Bittner, M., Chen, Y., Meltzer, P., and Trent, J. M. (1999). Expression profiling using cDNA microarrays. Nat. Genet. 21, 10-14.
104. Dummer, W., Bastian, B. C., Ernst, N., Schanzle, C., Schwaaf, A., and Brocker, E. B. (1996). Interleukin-10 production in malignant melanoma: preferential detection of IL-10-secreting tumor cells in metastatic lesions. Inf. J. Cancer 66, 607-610.
105. Dummer, W., Becker, J. C., Schwaaf, A., Leverkus, M., Moll, T., and Brocker, E. B. (1995). Elevated serum levels of interleukin-10 in patients with metastatic malignant melanoma. Melanoma Res. 5, 67-68.
106. Durrant, L. G., Ballantyne, K. C., Armitage, N. C., Robins, R. A., Marksman, R., Hardcastle, J. D., and Baldvin, R. W. (1987). Quantitation of MHC antigen expression on colorectal tumours and its association with tumour progression. Br. J. Cancer 56, 425-432.
107. D'Urso, C. M., Wang, Z. G., Cao, Y., Tatake, R., ZefT, R. A., and Ferrone, S. (1991). Lack of HLA class I antigen expression by cultured melanoma cells FO-1 due to a defect in B2m gene expression. J. Clin. Invest. 87, 284-292.
108. Effros, R. B., Allsopp, R., Chiu, C. P., Hausner, M. A., Hirji, K., Wang, L., Harley, C. B., Villeponteau, B., West, M. D., and Giorgi, J. V. (1996). Shortened telomeres in the expanded CD28-CD8+ cell subset in HIV disease implicate replicative senescence in HIV pathogenesis. AIDS 10, F17-F22.
109. Effros, R. B., and Pawelec, G. (1997). Replicative senescence of T cells: does the Hayflick Limit lead to immune exhaustion? Immunol. Today 18, 450-454.
110. Eisenbach, L., Hollander, N., Greenfeld, L., Yakor, H., Segal, S., and Feldman, M., (1984). The differential expression of H-2K versus H-2D antigens, distinguishing high-metastatic from low-metastatic clones, is correlated with the immunogenic properties of the tumor cells. Int. ]. Cancer 34, 567-573.
111. Eisenbach, L., Segal, S., and Feldman, M. (1983). MHC imbalance and metastatic spread in Lewis lung carcinoma clones. Int. J. Cancer 32, 113-120.
112. Ellison, M. D., Krieg, R. J., and Povlishock, J. T. (1990). Differential central nervous system responses following single and multiple recombinant interleukin-2 infusions. J. Neuroimmunol. 28, 249-260.
113. Esteban, F., Concha, A., Delgado, M., Perez-Ayala, M., Ruiz-Cabello, F., and Garrido, F. (1990). Lack of MHC class I antigens and tumour aggressiveness of the squamous cell carcinoma of the larynx. Br. J. Cancer 62, 1047-1051.
114. Esteban, F., Concha, A., Huelin, C., Perez-Ayala, M., Pedrinaci, S., Ruiz-Cabello, F., and Garrido, F. (1989). Histocompatibility antigens in primary and metastatic squamous cell carcinoma of the larynx. Int. ]. Cancer 43, 436-442.
115. Esteban, F., Redondo, M., Delgado, M., Garrido, F., and Ruiz-Cabello, F. (1996). MHC class I antigens and tumour-infiltrating leucocytes in laryngeal cancer: long-term followup. Br. J. Cancer 74, 1801-1804.
116. Färber, J. M. (1997). Mig and IP-10: CXC chemokines that target lymphocytes. ]. Leukoc. Biol. 61, 246-257.
117. Feldman, M. and Eisenbach, L. (1991). MHC class I genes controlling the metastatic phenotype of tumor cells. Semin. Cancer Biol. 2,'337-346.
118. Feltner, D. E., Cooper, M., Weber, J., Israel, M. A., and Thiele, C. J. (1989). Expression of class I histocompatibility antigens in neuroectodermal tumors is independent of the expression of a transfected neuroblastoma myc gene. J. Immunol. 143, 4292-4299.
119. Ferron, A., Perez-Ayala, M., Concha, A., Cabrera, T., Redondo, M., Oliva, M. R., RuizCabello, F., and Garrido, F. (1989). MHC class I and II antigens on gastric carcinomas and autologous mucosa.J. Immunogenet. 16, 413-423.
120. Ferrone, S., and Marincola, F. M. (1995). Loss of HLA class I antigens by melanoma cells: Molecular mechanisms, functional significance and clinical relevance. Immunol. Today 16, 487-494.
121. Fiorentino, D. F., Bond, M. W., and Mosmann, T. R. (1989). Two types of mouse T helper cell. IV. Th2 clones secrete a factor that inhibits cytokine production by Thl clones. J. Exp. Med. 170, 2081-2095.
122. Fisk, B., Blevins, T. L., Wharton, J. T., and loannides, C. G. (1995). Identification of an immunodominant peptide of HER-2/neu protooncogene recognized by ovarian tumorspecific cytotoxic T lymphocyte lines.J. Exp. Med. 181, 2109-2117.
123. Fleischhauer, K., Fruci, D., van Endert, P., Herman, J., Tanzarella, S., Wallny, H. J., Coulie, P., Bordignon, C., andTraversari, C. (1996). Characterization of antigenicpeptides presented by HLA-B44 molecules on tumor cells expressing the gene MAGE-3. Int. J. Cancer 68, 622-628.
124. Foa, R., Guarini, A., and Gansbacher, B. (1992). IL2 treatment for cancer: from biology to gene therapy. Er. J. Cancer 66, 992-998.
125. Francke, U., and Pellegrino, M. A. (1977). Assignment of the major histocompatibility complex to a region of the short arm of human chromosome 6. Proc. Natl. Acad. Sci. USA 74, 1147-1151.
126. Fuchs, E. J., and Matzinger, P. (1996). Is cancer dangerous to the immune system? Semin. Immunol. 8, 271-280.
127. Garboczi, D. N., Ghosh, P., Utz, U., Fan, Q. R., Biddison, W. E., and Wiley, D. C. (1996). Structure of the complex between human T-cell receptor, viral peptide and HLA-A2. Nature 384, 134-141.
128. Garrido, F., Cabrera, T., Accola, R. S., Bensa, J. C., Bodmer, W. F., Dohr, G., Drenou, B., Drouet, M., Fauchet, R., Ferrara, G. B., Ferrone, S., Giacomini, P., Kageshita, T., Koopman, L., Maio, M., Marincola, F. M., Mazzilli, C.; Morel, P. A., Murray, A., Papasteriades, C., Salvaneschi, L., Stern, P. L., and Ziegler, A. (1997). IILA and cancer: 12th International Histocompatibility Workshop study. In "Genetic Diversitity of HLA: Functional and Medical Implications," (D. Charron, ed.) 12 ed., pp. 445-452. EDK, Sevres, France.
129. Garrido, F., Festenstein, H., and Schirrmacher, V. (1976). Further evidence for depression of H-2 and la-like specificities of foreign haplotypes in mouse tumour cell lines. Nature 261, 705-707.
130. Garrido, F., Ferez, M., and Torres, M. D. (1979). Absence of four H-2d antigenic specificities in an H-2d sarcoma. J. Immunogenet. 6, 83-86.
131. Garrido, F., Ruiz-Cabello, F., Cabrera, T., Perez-Villar, J. J., Lopez-Nevot, M. A., Duggan-Keen, M., and Stern, P.L. (1997). Implications for immunosurveillance of altered HLA class I phenotypes in human tumours. Immunol. Today 18, 89-95.
132. Gastl, G., Ebert, T., Finstad, C. L., Sheinfeld, J., Gomahr, A., Aulitzky, W., and Bander, N. H. (1996). Major histocompatibility complex class I and class II expression in renal cell carcinoma and modulation by interferon gamma. J. Urol. 155, 361-367.
133. Gattoni-Celli, S., Kirsch, K., Timpane, R., and Isselbacher, K. J. (1992). Beta2-microglobulin gene is mutated in a human colon cancer cell line (HCT) deficient in the expression of IILA class I antigens on the cell surface. Cancer Res. 52, 1201-1204.
134. Gaugler, B., Van den Eynde, B., van der Bruggen, P., Romero, P., Gaforio, J. J., De Plaen, E., Lethe, B., Brasseur, F., and Boon, T. (1994). Human gene MAGE-3 codes for an antigen recognized on a melanoma by autologous cytolytic T lymphocytes. J. Exp. Med. 179, 921-930.
135. Germain, R. N. (1996). The ins and outs of antigen processing and presentation. Nature 322, 687-689.
136. Gervois, N., Guilloux, Y., Diez, E., and Jotereau, F. (1996). Suboptimal activation of melanoma infiltrating lymphocytes due to low avidity of TCR/MHC-tumor peptide interactions. J. Exp. Med. 183, 2403-2407.
137. Girdlestone, J., Isamat, M., Gewert, D., and Milstein, C. (1993). Transcriptional regulation of HLA-A and -B: Differential binding of members of the Rel and IRF families of transcription factors. Proc. Natl. Acad. Sei. USA 90, 11568-11572.
138. Gnjatic, S., Cai, Z., Viguier, M., Chouaib, S., Guillet, J. G., and Choppin, J. (1998). Accumulation of the p53 protein allows recognition by human CTL of a wild-type p53 epitope presented by breast carcinomas and melanomas. J. Immunol. 160, 328-333.
139. Gobin, S. J., Keijsers, V., van Zutphen, M., and Van den Eisen, P. J. (199Sa). The role of enhancer A in the locus-specific transactivation of classical and nonclassical HLA class I genes by nuclear factor kappa B. J. Immunol. 161, 2276-2283.
140. Gobin, S. J., Peijnenburg, A., van Eggermond, M., van Zutphen, M., van den Berg, R., and Van den Elsen, P. J. (199Sb). The RFX complex is crucial for the constitutive and CIITA-mediated transactivation of MHC class I andbeta2-microglobulin genes. Immunity 9, 531-541.
141. Goepel, J. R., Rees, R. C., Rogers, K., Stoddard, C. J., Thomas, W. E., and Shepherd, L. (1991). Loss of monomorphic and polymorphic HLA antigens in metastatic breast and colon carcinoma. Br. J. Cancer 64, 880-883.
142. Goodfellow, P. N., Jones, E. A., Van Heyningen, V., Solomon, E., Bobrow, M., Miggiano, V., and Bodmer, W. F. (1975). The beta2-microglobulin gene is on chromosome 15 and not in the HL-A region. Nature 254, 267-269.
143. Gorsch, S. M., Memoli, V. A., Stukel.T. A., Gold, L. I., and Arrick, B. A. (1992). Immunohistochemical staining for transforming growth factor beta 1 associates with disease progression in human breast cancer. Cancer Res. 52, 6949-6952.
144. Graf, L. II., and Ferrone, S. (19S9). Human melanoma associated antigens. In "Human Immunogenetics," (S. D. Litwin, éd.), pp. 643-679. Marcel Dekker, New York, Basel.
145. Gratas, C., Tohma, Y., Van Meir, E. G., Klein, M., Tenan, M., Ishii, N., Tachibana, O., Kleihues, P., and Ohgaki, H. (1997). Fas ligand expression in glioblastoma cell lines and primary astrocytic brain tumors. Brain Pathol. 1, 863-869.
146. Guilloux, Y., Lucas, S., Brichard, V. G., Van Pel, A., Viret, C., De Plaen, E., Brasseur, F., Lethe, B., Jotereau, F., and Boon, T. (1996). A peptide recognized by human cytolytic T lymphocytes on HLA-A2 melanomas is encoded by an intron sequence of the N-acetylglucosaminyltransferase V gene. J. Exp. Med. 183, 1173-1183.
147. Gwin, J. L., Gercel-Taylor, C., Taylor, D. D., and Eisenberg, B. (1996). Role of LFA-3, ICAM-1, and MHC class I on the sensitivity of human tumor cells to LAK cells.J. Surg. Res. 60, 129-136.
148. Hahne, M., Rimoldi, D., Schroter, M., Romero, P., Schreier, M., French, L. E., Schneider, P., Bomand, T., Fontana, A., Lienard, D., Cerottini, J.-C., and Tschopp, J. (1996). Melanoma cell expression of Fas (Apo-l/CD95) ligand: Implications for tumor immune escape. Science 274, 1363-1366.
149. Hakem, R., Jezo-Bremond, A., Le Bouteiller, P., Harper, K., and Lemonnier, F. A. (1991). Differential transcription inducibility by interferori of the HLA-A3 and HLA-B7 class-I genes. Int. J. Cancer Suppl. 6, 2-9.
150. Haywood, G. R., and McKhann, C. F. (1971). Antigenic specificities on murine sarcoma cells. Reciprocal relationship between normal transplantation antigens (H-2) and tumorspecific immunogenicity. J. Exp. Med. 133, 1171-1187.
151. Hellstrom, K. E. (1960). Studies on isoantigenic variation in mouse lymphoma. J. Natl. Cancer Inst. 25, 237-269.
152. Henseling, U., Schmidt, W., Scholer, II. R., Gruss, P., and Hatzopoulos, A. K. (1990). A transcription factor interacting with the class I gene enhancer is inactive in tumorigenic cell lines which suppress major histocompatibility complex class I genes. Mol. Cell Biol. 10, 4100-4109.
153. Herlyn, M., and Koprowski, H. (1988). Melanoma antigens: Immunological and biological characterization and clinical significance. Anna. Rev. Immunol. 6, 283-308.
154. Hicklin, D. J., Dellaratta, D. V., Kishore, R., Liang, B., Kagcsliita, T., and Ferrone, S. (1997). Beta2-microglobulin gene mutations in human melanoma cells: molecular characterization and implications for immune surveillance. Melanoma Res. 1 Suppl 2, S67-S74.
155. Hicklin, D. J., Wang, Z., Arienti, F., Rivoltini, L., Parmiani, G., and Ferrone, S. (199S). Beta2-microglobulin mutations, HLA class I antigen loss, and tumor progression in melanoma. J. Clin. Incest. 101, 2720-2729.
156. Hilders, C. G., Houbiers, J. G., Krul, E. J., and Fleuren, G. J. (1994). The expression of histocompatibility-related leukocyte antigens in the pathway to cervical carcinoma. Am. J. Clin. Pathol. 101, 5-12.
157. Hilders, C. G., Munoz, I. M., Nooyen, Y., and Fleuren, G. J. (1995). Altered HLA expression by metastatic cervical carcinoma cells as a factor in impaired immune surveillance. Gynccol. Oncol. 57, 366-375.
158. Holzmann, B., Brocker, E. B., Lehmann, J. M., Ruiter, D. J., Sorg, C., Riethmuller, G., and Johnson, J. P. (1987). Tumor progression in human malignant melanoma: five stages defined by their antigenic phenotypes. Int. J. Cancer 39, 466-471.
159. Honma, S., Tsukada, S., Honda, S., Nakamura, M., Takakuwa, K., Maruliaslii, T., Kodama, S., Kanazawa, K., Takahashi, T., and Tanaka, K. (1994). Biological-clinical significance of selective loss of HLA-class-I allelic product expression in squamous-cell carcinoma of the uterine cervix. Int. J. Cancer 57, 650-655.
160. Houck, J. R., Sexton, F. M., and Zajdel, G. (1990). HLA class I and class II antigen expression on squamous cell carcinoma of the head and neck. Arch. Otolanjngol. Head, Neck Surg. 116, 1181-1185.
161. Huang, A. Y., Gulden, P. H., Woods, A. S., Thomas, M. C., Tong, C. D., Wang, W., Engelhard, V. IL, Pasternack, G., Cotter, R., Hunt, D., Pardoll, D. M., and Jaffee, E. M. (1996). The immunodominant major histocompatibility complex class I-restricted antigen of a murine colon tumor derives from an endogenous retroviral gene product. Proc. Natl. Acad. Sei. USA 93, 9730-9735.
162. Hui, K., Grosveld, F., and Festenstein, H. (1984). Rejection of transplantable AKR leukaemia cells following MHC DNA-mediated cell transformation. Nature 311, 750-752.
163. Hui, K. M. (1989). Re-expression of major histocompatibility complex (MHC) class I molecules on malignant tumor cells and its effect on host-tumor interaction. Bioessays 11, 22-26.
164. Hung, K., Hayashi, R., Lafond-Walker, A., Lowenstein, C., Pardoll, D., and Levitsky, II. (1998). The central role of CD4+ T cells in the antitumor immune response. J. Exp. Med. 188, 2357-2368.
165. Hunt, D. F., Henderson, R. A., Shabanowitz, J., Sakaguchi, K., Michel, H., Sevilir, N., Cox, A. L., Appella, E., and Engelhard, V.'H. (1992). Characterization of peptides bound to the class I MHC molecule HLA-A2.1 by mass spectrometry. Science 255, 1261-1263.
166. Ikeda, H., Lethe, B., Lehmann, F., van Baren, N., Baurain, J. F., De Smet, C., Chambost, H., Vitale, M., Moretta, A., Boon, T., and Coulie, P. G. (1997). Characterization of an antigen that is recognized on a melanoma showing partial HLA loss by CTL expressing an NK inhibitory receptor. Immunity 6, 199-208.
167. Jager, E., Chen, Y. T., Drijfhout, J. W., Karbach, J., Ringhoffer, M., Jager, D., Arand, M., Wada, H., Naguchi, Y., Stockert, E., Old, L. J., and Knuth, A. (1998). Simultaneous humoral and cellular immune response against Cancer-Testis antigen NY-ESO-1: Definition of human histocompatibility leukocyte antigen (IILA)-A2-binding peptide epitopes. J. Exp. Med. 187, 265-275.
168. Jager, E., Ringhoffer, M., Altmannsberger, M., Arand, M., Karbach, J., Jager, D., Oesch, F., and Knuth, A. (1997). Immunoselection in vivo: Independent loss of MHC class I and melanocyte differentiation antigen expression in metastatic melanoma. Int. ]. Cancer 71, 142-147.
169. Jager, E., Ringhoffer, M., Karbach, J., Arand, M., Oesch, F., and Knuth, A. (1996). Inverse relationship of melanocyte differentiation antigen expression in melanoma tissues and CD8+ cytotoxic-T-cell responses: evidence for immunoselection of antigen-loss variants in vivo. Int. J. Cancer 66, 470-476.
170. Joh'nsen, A., France, J., Sy, M. S., and Harding, C. V. (1998). Down-regulation of the transporter for antigen presentation, proteasome subunits, and class I major histocompatibility complex in tumor cell lines. Cancer Res. 58, 3660-3667.
171. Johnson, J. P. (1991). The role of ICAM-1 in tumor development. Chem. Immunol. 50, 143-163.
172. Kabawat, S. E., Bast, R. C. J., Welch, W. R., Knapp, R. C., and Bhan, A. K. (19S3). Expression of major histocompatibility antigens and nature of inflammatory cellular infiltrate in ovarian neoplasms. Int. J. Cancer 32, 547-554.
173. Kageshita, T., Hirai, S., Ono, T., Hicklin, D. J., and Ferrone, S. (1999). Downregulation of HLA class I antigen processing molecules in malignant melanoma. Association with disease progression. Am. J. PatJiol. 154(3):745-754.
174. Kaklamanis, L., Gatter, K. C., Hill, A. B., Mortensen, N., Harris, A. L., Krausa, P., McMichael, A., Bodmer, J. G., and Bodmer, W. F. (1992). Loss of HLA class-I%alleles, heavy chains and beta 2-microglobulin in colorectal cancer. Int. J. Cancer 51, 379-385.
175. Kaklamanis, L., Leek, R., Koukourakis, M., Gatter, K. C., and Harris, A. L. (1995). Loss of transporter in antigen processing 1 transport protein and major histocompatibility complex class I molecules in metastatic versus primary breast cancer. Cancer Res. 55, 5191-5194.
176. Kaklamanis, L., Townsend, A., Doussis-Anagnostopoulou, I. A., Mortensen, N., Harris, A. L., and Gatter, K. C. (1994). Loss of major histocompatibility complex-encoded trans-porter associated with antigen presentation (TAP) in colorectal cancer. Am. ]. Pathol. 145, 505-509.
177. Kalams, S. A. and Walker, B. D. (1998) The critical need for CD4 help in maintaining effective cytotoxic T lymphocyte responses. J. Exp. Med. 188, 2199-2204.
178. Kang, X., Kawakami, Y., el-Gamil, M., Wang, R., Sakaguchi, K., Yannelli, J. R., Appella, E., Rosenberg, S. A., and Robbins, P. F. (1995). Identification of a tyrosinase epitope recognized by HLA-A24- restricted, tumor-infiltrating lymphocytes. J. Immunol. 155, 1343-1348.
179. Kawakami, Y., Battles, J. K., Kobayashi, T., Ennis, W., Wang, X., Tupesis, J. P., Marincola, F. M., Robbins, P. F., Hearing, V. J., Gonda, M..A., and Rosenberg, S. A. (1997). Production of recombinant MART-1 proteins and specific antiMART-1 polyclonal and monoclonal antibodies: use in the characterization of the human melanoma antigen MART-1.J. Immunol. Methods 202, 13-25.
180. Kawakami, Y., Eliyahu, S., Delgado, C. H., Robbins, P. F., Sakaguchi, K., Appella, E., Yannelli, J. R., Adema, G. J., Mild, T., and Rosenberg, S. A. (1994a). Identification of a human melanoma antigen recognized by tumor-infiltrating lymphocytes associated with in vivo tumor rejection. Proc. Natl. Acad. Sei. USA 91, 6458-6462.
181. Kawakami, Y., Eliyahu, S., Jennings, C., Sakaguchi, K., Kang, X., Southwood, S., Robbins, P. F., Sette, A., Appella, E., and Rosenberg, S. A. (1995). Recognition of multiple epitopes in the human melanoma antigen gplOO by tumor-infiltrating T lymphocytes associated with in vivo tumor regression. J. Immunol. 154, 3961-3968.
182. Kawakami, Y, Eliyahu, S., Sakaguchi, K., Robbins, P. F., Rivoltini, L., Yannelli, J. R., Appella, E., and Rosenberg, S. A. (1994b). Identification of the immunodominant peptides of the MART-1 human melanoma antigen recognized by the majority of HLA-A2-restricted tumor infiltrating lymphocytes.J. Exp. Med. 180, 347-352.
183. Kawakami, Y., Bobbins, P. F., Wang, X., Tupesis, J. P., Parkhurst, M. R., Kang, X., Sakaguchi, K., Appella, E., and Rosenberg, S. A. (1998). Identification of new melanoma epitopes on melanosomal proteins recognized by tumor infiltrating lymphocytes restricted by HLA-Al, -A2 and -A3 alleles. J. Immunol. 161, 6985-6992.
184. Keating, P. J., Cromme, F. V., Duggan-Keen, M., Snijders, P. J., Walboomers, J. M., Hunter, R. D., Dyer, P. A., and Stem, P. L. (1995). Frequency of down-regulation of individual HLA-A and -B alleles in cervical carcinomas in relation to TAP-1 expression. Br. J. Cancer 72, 405-411.
185. Kern, F., Surel, I. P., Brock, C., Freistedt, B., Radtke, H., Scheffold, A., Blasczyk, B., Beinke, P., Schneider-Mergener, J., Badbruch, A., Waiden, P., and Volk, H.D. (1998). T-cell epitope mapping by flow cytometry. Nat. Med. 4, 975-978.
186. Kilgore, K. S., Shen, J. P., Miller, B. F., Ward, P. A., and Warren, J.S. (1995). Enhancement by the complement membrane attack complex of tumor necrosis factor-alpha-induced endothelial cell expression of E-selectin and ICAM-1.J. Immunol. 155, 1434-1441.
187. Kim, C. J., Parkinson, D. B., and Marincola, F. M. (1997). Immunodominance across the HLA polymorphism: Implications for cancer immunotherapy. J. Immunother. 21, 1-16.
188. Kim, C. J., Taubenberger, J. K., Simonis, T. B., White, D. E., Bosenberg, S. A., and Marincola, F. M. (1996). Combination therapy with Interferon-gamma and Interleukin-2 for the treatment of metastatic melanoma. J. Immunother. 19, 50-58.
189. Kitsuki, H., Katano, M., Ikubo, A., Morisaki, T., Anann, K., Tanaka, M., and Torisu, M. (1996). Induction of inflammatory cytokines in effusion cavity by OK-432 injection therapy for patients with malignant effusion: Bole of interferon-gamma in enhancement of surface expression of ICAM-1 on tumor cells in vivo. Clin. Immunol. Immunopathol. 78,283-290.
190. Klein, B., Klein, T., Konichezky, M., Nyska, A., Livini, E., Levine, I., Zamir, B., Kooperman, O., and Lurie, H. (1990). The expression of HLA class I antigens in germ cell testicular cancer. Am. ]. Clin. Pathol 93, 202-207.
191. Klein, B., Zhang, X. G., jourdan, M., Content, J., Houssiau, F., Aarden, L., Piechaczyk, M., and Bataille, R. (1989). Paracrine rather than automne regulation of myeloma-cell growth and differentiation by interleukin-6. Blood 73, 517-526.
192. Klein, E., Klein, G., and Hellstrom, K. E. (1960). Further studies on isoantigenic variation in mouse carcinomas and sarcomas. J. Natl. Cancer Inst. 25, 271-294.
193. Koopman, L. A., Mulder, A., Corver, W. E., Anholts, J. D., Giphart, M. J., Claas, F. H., and Fleuren, G. J. (1998). HLA class I phenotype and genotype alterations in cervical carcinomas and derivative cell lines. Tissue Antigens 51, 623-636.
194. Korkolopoulou, P., Kaklamanis, L., Pezzella, F., Harris, A.L., and Gatter, K. C. (1996). Loss of antigen-presenting molecules (MHC class I and TAP-1) in lung cancer. Br. J. Cancer 73, 148-153.
195. Krunkosky, T. M., Fischer, B. M., Akley, N. J., and Adler, K. B. (1996). Tumor necrosis factor alpha (TNF alpha)-induced ICAM-1 surface expression in airway epithelial cells n vitro: Possible signal transduction mechanisms. Ann. NY Acad. Sei. 796, 30-37.
196. Kruse, N., Pette, M., Toyka, K., and Bieckmann, P. (1997). Quantification of cytokine mRNA expression by BT PCB in samples of previously frozen blood.J. Immunol. Methods 210, 195-203.
197. Krutmann, J., Kock, A., Schauer, E., Parlow, F., Moller, A., Kapp, A., Forster, E., Schopf, E., and Luger, T. A. (1990). Tumor necrosis factor beta and ultraviolet radiation are potent regulators of human keratinocyte ICAM-1 expression.J. Invest. Dennatol. 95, 127-131.
198. Kurokohchi, K., Carrington, M., Mann, D. L., Simonis, T. B., Alexander-Miller, M. A., Feinstone, S. M., Akatsuka, T., and Berzofsky, J. A. (1996). Expression of HLA class I molecules and the transporter associated with antigen processing in hepatocellular carcinoma. Hcpatology 23, 1181-1188.
199. Kurts, C., Heath, W. R., Carbone, F. R., Kosaka, IL, and Miller, J. F. (199S). Crosspresentation of self antigens to CD8+ T cells: the balance between tolerance and autoimmunity. Nocartis. Found. Symji. 215, 172-181.
200. Kurts, C., Kosaka, H., Carbone, F. R., Miller, J. F., and Heath, W. R. (1997). Class I-restricted cross-presentation of exogenous self-antigens leads to deletion of autoreactive CD8( + ) T cells. J. Erp. Mal. 186, 239-245.
201. Labarriere, N., Pandolfino, M. C., Raingeard, D., Le Guiner, S., Diez, E., Le Drean, E., Dreno, B., and Jotereau, F. (1998). Frequency and relative fraction of tumor antigen-specific T cells among lymphocytes from melanoma-invaded lymph nodes. Int. J. Cancer 78, 209-215.
202. Laforet, M., Froelich, N., Parissiadis, A., Pfeiffer, B., Schell, A., Faller, B., Woehl-Jaegle, M. L., Cazenave, J. P., and Tongio, M. M. (1997). A nucleotide insertion in exon 4 is responsible for the absence of expression of an HLA-A01 allele. Tissue Antigens 50, 347-350.
203. Lai, F. M., Cheng, P. N., Tsao, S. Y., and Lai, K. N. (1990). Immunohistological characteristics of the infiltrating lymphoid cells and expression of HLA class I and II antigens in nasopharyngeal carcinoma. 7irchows Arch.A Pathol. Anat. Histopathol. 417, 347-352.
204. Lanier, L. L. (1998). Follow the leader: NK cell receptors for classical and nonclassical MHC class I. Cell 92, 705-707.
205. Lanier, L. L., and Phillips, J. H. (1996). Inhibitory MHC class I receptors on NK cells and T cells. Immunol. Today 17, 86-91.
206. Lauritzsen, G.F., Hofgaard, P. O., Schenck, K., and Bogen, B. (1998). Clonal deletion of thymocytes as a tumor escape mechanism. Int. J. Cancer 78, 216-222.
207. Lee, K.-H., Panelli, M. C., Kim, C. J., Riker, A., Roden, M., Fetsch, P. A., Abati, A., Bettinotti, M. P., Rosenberg, S. A., and Marincola, F. M. (1998). Functional dissociat ion between local and systemic immune response following peptide vaccination.J. Immunol. 161, 4183-4194.
208. Lefor, A. T., and Fabian, D. F. (199S). Enhanced cytolytic activity of tumor infiltrating lymphocytes derived from an ICAM-1 transfected tumor in a murine model. J. Surg. Res. 75, 49-53.
209. Lehmann, F., Marchand, M., Hainaut, P., Fouillait, P., Sastre, X., Ikeda, H., Boon, T., and Coulie, P. G. (1995). Differences in the antigens recognized by cytolytic T cells on two successive métastases of a melanoma patient are consistent with immune selection. Eur. J. Immunol. 25, 340-347.
210. Lenardo, M., Rustgi, A. K., Schievella, A. R., and Bernards, R. (1989). Suppression of MHC class I gene expression by N-myc through enhancef inactivation. EMBOJ. 8,3351-3355.
211. Lengauer, C., Kinzler, K. W., and Vogelstein, B. (1998). Genetic instabilities in human cancers. Nature 396, 643-649.
212. Lethe, B., Van den Eynde, B., Van Pel, A., Corradin, G., and Boon, T. (1992). Mouse tumor rejection antigens P815A and P815B: two epitopes carried by a single peptide. Eur. ]. Immunol. 22, 2283-2288.
213. Lethe, B., van der Bruggen, P., Brasseur, F., and Boon, T. (1997). MAGE-1 expression threshold for the lysis of melanoma cell lines by a specific cytotoxic T lymphocyte. Melanoma. Res. 1 Sup 2, S83-S88.
214. Levine, A. J. (1989). The SV40 large tumor antigen. In "Molecular Biology of Chromosome Function.," (K. W. Adolph, ed.), pp. 71-96. Springer-Verlag, New York.
215. Lienert, K., Russ, G., Lester, S., Bennett, G., Gao, X., and McCIuskey, J. (1996). Stable inheritance of an HLA-"blank" phenotype associated with a structural mutation in the HLA-A0301 gene. Tissue Antigens 48, 187-191.
216. Liteplo, R. G., and Kerbel, R. S. (1987). Reduced levels of DNA 5-inethylcytosine in metastatic variants of the human melanoma cell line MeWo. Cancer Res. 47,2264-2267.
217. Livingston, P. O. (1998). The case for melanoma vaccines that induce antibodies. In "Molecular Diagnosis, Prevention and Treatment of Melanoma," ( J. M. Kirkvvood, ed.) pp. 139-157. Mural Decker, Inc.
218. Livingston, P. O., Wang, G. Y. C., Adluri, S., Too, Y., Padavan, M., Parente, R., Hanion, C., Calves, M. J., Helling, F., Ritter, G., Oettgen, H. F., and Old, L. J. (1994). Improved survival in stage III melanoma patients with GM2 antibodies: a rondomized trial of adjuvant vaccination with GM2 ganglioside. J. Clin. Oncol. 12, 1036-1044.
219. Ljunggren, H. G., and Karre, K. (19S5). Host resistance directed selectively against H-2deficient lymphoma variants. Analysis of the mechanism. ). Exp. Med. 162, 1745-1759.
220. Lo, S. K., Everitt, J., Gu, J., and Malik, A. B. (1992). Tumor necrosis factor mediates experimental pulmonary edema by ICAM-1 and CDlS-dependent mechanisms.J. Clin. Invest. 89, 981-988.
221. Loftus, D. J., Castelli, C., Clay, T. M., Squarcina, P., Marincola, F. M., Nishimura, M. L, Parmiani, G., Appella, E., and Rivoltini, L. (1996). Identification of epitope mimics recognized by CTL reactive to the melanoma/melanocyte-derived peptide MART-1(27-35). J. Exp. Med. 184, 647-657.
222. Loftus, D. J., Squarcina, P., Nielsen, M. B., Geisler, C., Castelli, C., Odum, N., Appella, E., Parmiani, G., and Rivoltini, L. (1998). Peptides derived from self-proteins as partial agonists and antagonists of human CD8+ T-cell clones reactive to melanoma/melanocyte epitope MARTl(27-35). Cancer Res. 58, 2433-2439.
223. Lopez-Botet, M., Moretta, L, and Strominger, J. (1996). NK-cell receptors and recognition of MHC class I molecules. Immunol. Today 17, 212-214.
224. Lopez-Nevot, M. A., Esteban, F., Ferron, A., Gutierrez, J., Oliva, M. R., Romero, C., Huelin, C., Ruiz-Cabello, F., and Garrido, F. (19S9). HLA class I gene expression on human primary tumours and autologous métastases: Demonstration of selective losses of HLA antigens on colorectal, gastric and laryngeal carcinomas. Br. J. Cancer 59,221-226.
225. Luboldt, H. J., Kubens, B. S., Rubben, IL, and Grosse-Wilde, H. (1996). Selective loss of human leukocyte antigen class I allele expression in advanced renal cell carcinoma. Cancer Res. 56, 826-830.
226. Lupetti, R., Pisarra, P., Verrecchia, A., Farina, C., Nicolini, G., Anichini, A., Bordignon, C., Sensi, M., Parmiani, G., and Traversari, C. (1998). Translation of a retained intron in tyrosinase-related protein (TRP) 2 mRNA generates a new cytotoxic T lymphocyte (CTL)-defined and shared human melanoma antigen not expressed in normal cells of the melanocytic lineage. J. Exp. Med. 188, 1005-1016.
227. Lurquin, C., Van Pel, A., Mariame, B., DeTlaen, E., Szikora, J. P., Janssens, C., Reddehase, M. J., Lejeune, J., and Boon, T. (1989). Structure of the gene of turn- transplantation antigen P91A: The mutated exon encodes a peptide recognized with Ld by cytolytic T cells. Cell 58, 293-303.
228. Lyons, D. S., Lieberman, S. A., Hampl, J., Boniface, J. J., Chien, Y., Berg, L. J., and Davis, M. M. (1996). A TCR binds to antagonist ligands with lower affinities and faster dissociation rates than to agonists. Immunity. 5, 53-61.
229. Magor, K. E., Taylor, E. J., Shen, S. Y., Martinez-Naves, E., Variante, N. M., Wells, R. S., Gumperz, J. E., Adams, E. J., Little, A. M., Williams, F., Middleton, D., Gao, X., McCluskey, J., Parham, P., and Uenert-Weidenbach, K. (1997). Natural inactivation of a common HLA allele (A2402) has occurred on at least three separate occasions. J. Immunol. 158, 5242-5250.
230. Maio, M., Altomonte, M., Tatake, R., Zeff, R. A., and Ferrone, S. (1991). Reduction in susceptibility to natural killer cell-mediated lysis of human FO-1 melanoma cells after induction of IILA class I antigen expression by transfection with B2m gene. J. Clin. Invest. 88, 282-289.
231. Maio, M., Gulwani, B., Morgano, A., and Ferrone, S. (1989a). Differential modulation by tumor necrosis factor and immune interferon of HLA class-II antigens expressed by melanoma cells. Int. J. Cancer. 44, 554-559.
232. Maio, M., Gulwani, B., Tombesi, S., and Ferrone, S. (1989b). Modulation by cytokines of HLA antigens, intercellular adhesion molecule 1 and high molecular weight melanoma associated antigen expression and of immune lysis of clones derived from the melanoma cell line MeM 50-10. Cancer Immunol. Immunother. 30, 34-42.
233. Maiorana, A., Cesinaro, A. M., Fano, R. A., and Collina, G. (1995). Expression of MHC class I and class II antigens in primary breast carcinomas and synchronous nodal métastases. Clin. Exp. Metastasis 13, 43-48.
234. Mandelboim, O., Pazmany, L., Davis, D. M., Vales-Gomez, M., Reybum, H. T., Rybalov, B., and Strominger, J. L. (1997). Multiple receptors for HLA-G on human natural killer cells. Proc. Natl. Acad. Sei. USA 94, 14666-14670.
235. Mandruzzato, S., Brasseur, F., Andry, G., Boon, T., and van der Bruggen, P. (1997). A CASP-8 mutation recognized by cytolytic T lymphocytes on a human head and neck carcinoma. J. Exp. Med. 186, 785-793.
236. Marchand, M., Weynants, P., Rankin, E., Arienti, F., Belli, F., Parmiani, G., Cascinelli, N., Bourlond, A., Vamvijck, R., and Humblet, Y. (1995). Tumor regression responses in melanoma patients treated with a peptide encoded by gene MAGE-3 [letter]. Int. J. Cancer 63, 883-885.
237. Marincola, F. M. (1997). The multiple ways to tumor tolerance.J. Immunother. 20,178-179.
238. Marincola, F. M., Hijazi, Y. M., Fetsch, P., Salgaller, M. L., Rivoltini, L., Cormier, J. N., Simonis, T. B., Duray, P. H., Herlyn, M., Kawakami, Y., and Rosenberg, S. A. (1996a). Analysis of expression of the melanoma associated antigens MART-1 and gp 100 in metastatic melanoma cell lines and in in situ lesions. J. Immunother. 19, 192-205.
239. Marincola, F. M., Rivoltini, L., Salgaller, M. L., Player, M. and Rosenberg, S. A. (1996b). Differential anti-MART-1/MelanA CTL activity in peripheral blood of HLA-A2 melanoma patients in comparison to healthy donors: Evidence for in vivo priming by tumor cells. ). Immunother. 19, 266-277.
240. Marincola, F. M., Shamamian, P., Alexander, R. B., Gnarra, J. R., Turetskaya, R. L., Nedospasov, S. A., Simonis, T. B., Taubenberger, J. K., Yannelli, J., Mixon, A., Restifo, N. P., Herlyn, M., and Rosenberg, S. A. (1994a). Loss of HLA haplotype and B locus down-regulation in melanoma cell lines. J. Immunol 153, 1225-1237.
241. Marincola, F. M., Shamamian, P., Simonis, T. B., Abati, A., Hackett, J., O'Dea, T., Fetsch, P., Yannelli, J., Restifo, N. P., Mule, J. J., and Ro'senberg, S. A. (1994b). Locus-specific analysis of human leukocyte antigen class I expression in melanoma cell lines. J. Immunother. 16, 13-23.
242. Matsushita, S., Kohsaka, H., and Nishimura, Y. (1997). Evidence for self and nonself peptide partial agonists that prolong clonal survival of mature T cells in vitro. J. Immunol. 158, 5685-5691.
243. Mattijssen, V., De Mulder, P. H., Schalkwijk, L., Manni, J. J., Van 't, H. and Ruiter, D. J. (1991). HLA antigen expression in routinely processed head and neck squamous cell carcinoma primary lesions of different sites. Int. J. Cancer Suppl. 6, 95-100.
244. Matzinger, P. (1994). Tolerance, danger, and the extended family. Anna. Rev. Immunol. 12, 991-1045.
245. Maurer, G. A., Friess, H., Kretschmann, B., Wildi, S., Muller, C., Graber, H., Schilling, M., and Buchler, M. W. (1998). Over-expression of ICAM-1, VCAM-1 and ELAM-1 might influence tumor progression in colorectal cancer. Int. J. Cancer 79, 76-81.
246. McDougall, G. J., Ngoi, S. S., Goldman, I. S., Godwin, T., Felix, J., DeCosse, J. J., and Rigas, B. (1990). Reduced expression of HLA class I and II antigens in colon cancer. Cancer Res. 50, 8023-8027.
247. McRae, B. L., Vanderlugt, G. L., Dal Canto, M. C., and Miller, S. D. (1995). Functional evidence for epitope spreading in the relapsing pathology of experimental autoimmune encephalomyelitis. J. Exp. Med. 182, 75-85.
248. Mechtersheimer, G., Staudter, M., Majdic, O., Dorken, B., Moldenhauer, G., and Moller, P. (1990). Expression of HLA-A, B, C, beta 2-microglobulin (beta 2m), HLA-DR, -DP, -DQ and of HLA-D-associated invariant chain (li) in soft-tissue tumors. Int. ]. Cancer 46, 813-823.
249. Mine, H., Ishikawa, Y., Hojo, M., Imashuku, S., Tokunaga, K., Juji, T., Saji, II., and Yokoyama, S. (1997) An HLA-B null allele (B"1526N) with a stop codon in exon'3 generated by a point mutation. Tissue Antigens 50, 351-354.
250. Mittelman, A., Chen, Z. J., Yang, II., Wong, G. Y., and Ferrone, S. (1992). Human high molecular weight melanoma-associated antigen (HMW-MAA) mimicry by mouse anti-idiotypic monoclonal antibody MK2-23: Induction of humoral anti-HMW-MAA immunity and prolongation of survival in patients with stage IV melanoma. Proc. Natl. Acad. Sei. USA 89, 466-470.
251. Moller, P., Momburg, F., Koretz, K., Moldenhauer, G., Herfarth, C., Otto, H. F., Hammerling, G. J., and Schlag, P. (1991). Influence of major histocompatibility complex class I and II antigens on survival in colorectal carcinoma. Cancer Res. 51, 729-736.
252. Momburg, F., Degener, T., Bacchus, E., Moldenhauer, G., Hammerling, G. J., and Moller, P. (1986). Loss of HLA-A, B, C and de novo expression of HLA-D in colorectal cancer. Int. J. Cancer 37, 179-184.
253. Momburg, F., Ziegler, A., Harpprecht, J., Moller, P., Moldenhauer, G., and Hammerling, G. J. (19S9). Selective loss of HLA-A or HLA-B antigen expression in colon carcinoma. ]. Immunol. 142 352-358.
254. Moretta, A., Biassoni, R., Bottino, C., Pende, D., Vitale, M., Poggi, A., Mingari, M. C., and Moretta, L. (1997). Major histocompatibility complex class I-specific receptors on human natural killer and T lymphocytes. Immunol. Rev. 155, 105-117.
255. Moretti, S., Pinzi, C., Berti, E., Spallanzani, A., Chiarugi, A., Boddi, V., Reali, U. M., and Giannotti, B. (1997). In situ expression of transforming growth factor beta is associated with melanoma progression and correlates with Ki67, HLA-DR and beta 3 integrin expression. Melanoma Res. 7, 313-321.
256. Morioka, N., Kikumoto, Y., Hoon, D. S., Morton, D. L., and Irie, R. F. (1994). A decapeptide (Gln-Asp-Leu-Thr-Met-Lys-Tyr-Gln-IIe-Phe) from human melanoma is recognized by CTL in melanoma patients. J. Immunol. 153, 5650-5658.
257. Mortarini, R., Belli, F., Parmiani, G., and Anichini, A. (1990). Cytokine-mediated modulation of HLA-class II, ICAM-1, LFA-3 and tumor-associated antigen profile of melanoma cells. Comparison with anti-proliferative activity by rILl-beta, rTNF-alpha, rIFN-gamma, rIL4 and their combinations. Int. J. Cancer 45, 334-341.
258. Moskophidis, D., Lechner, F., Pircher, H. P., and Zinkernagel, R. M. (1993). Virus persistence in acutely infected immunocompetent mice by exhaustion of antiviral cytotoxic effector T cells. Nature 362, 758-761.
259. Möller, E., and Möller, G. (1962). Quantitative studies of the sensitivity of normal and neoplastic mouse cells to the cytotoxic action of isoantibodies.J. Exp. Med. 115,527-553.
260. Münz, C., Holmes, N., King, A., Loke, Y. W., Colonna, M., Schild, H., and Rammensee, H. G. (1997). Human histocompatibility leukocyte antigen (HLA)-G molecules inhibit NKAT3 expressing natural killer cells. J. Exp. Med. 185, 385-391.
261. Natali, P. G., Digotti, A., Nicotra, M. R., Viora, M., Manfredi, D., and Ferrone, S. (1984). Distribution of human Class I (IILA-A, B, C) histocompatibility antigens in normal and malignant tissues of nonlymphoid origin. Cancer Res. 44, 4679-4687.
262. Natali, P., Bigotti, A., Cavalière, R., Liao, S. K., Taniguchi, M., Matsui, M., and Ferrone, S. (1985). Heterogeneous expression of melanoma-associated antigens and HLA antigens by primary and multiple metastatic lesions removed from patients with melanoma. Cancer Res. 45, 2883-2889.
263. Natali, P. G., Cavalière, R., Bigotti, A., Nicotra, M. R., Russo, C., Ng, A. K., Giacomini, P., and Ferrone, S. (19S3). Antigenic heterogeneity of surgically removed primary and autologous metastatic human melanoma lesions.J. Immiinol. 130, 1462-1466.
264. Natali, P. G., Nicotra, M. R., Bigotti, A., Ventura, L, Marcenaro, L., Giacomini, P., and Russo, C. (1989). Selective changes in expression of HLA class I polymorphic determinants in human solid tumors. Proc. Natl. Acad. Sei. USA 86, 6719-6723.
265. Nawroth, P., Handley, D., Matsueda, G., De Waal, R., Gerlach, IL, Blohm, D., and Stem, D. (1988). Tumor necrosis factor/cachectin-induced intravascular fibrin formation in meth A fibrosarcomas. J. Exp. Med. 168, 637-647.
266. Nestle, F. O., Alijagic, S., Gilliet, M., Sun, Y., Grabbe, S., Dummer, R., Burg, G., and Schadendorf, D. (1998). Vaccination of melanoma patients with peptide- or tumor lysatepulsed dendritic cells. Nat. Med. 4, 328-332.
267. Niehans, G. A., Brunner, T., Frizelle, S. P., Liston, J. C., Salemo, C. T., Knapp, D. J., Green, D. R., and Kratzke, R. A. (1997). Human lung carcinomas express Fas ligand. Cancer Res. 57, 1007-1012.
268. Nistico', P., Mottolese, M., Mammi, C., Benevolo, M., DelBello, D., Rublu, O., Gentile, F.P., Botti, C., Ventura, L, and Natali, P. G. (1997). Low frequency of ErbB-2 protooncogene overexpression in human leukocyte antigen A2 positive breast cancer patients. J. Natl. Cancer Inst. 89, 319-321.
269. O'Connell, J., O'Sullivan, G. C., Collins, J. K., and Shanahan, F. (1996). The Fas counterattack: Fas-mediated T cell killing by colon cancer cells expressing Fas ligand.J. Exp. Med. 184, 1075-1082.
270. O'Sullivan, G. C., Corbett, A. R., Shanahan, F. and Collins, J. K. (1996). Regional immunosuppression in esophageal squamous cancer: Evidence from functional studies with matched lymph nodes. J. Immiinol. 157, 4717-4720.
271. Ohmori. T., Okada, K., Arita, N., Watanabe, Y., Miyazaki, T., and Tabei, R. (1995). Characteristics of MIIC antigen expression and tumor-infiltrating mononuclear cells in renal cell adenomas and carcinomas, llistol. Histopathol. 10, 789-794.
272. Old, L. J., and Chen, Y. T. (1998). New paths in human cancer serology. J. Exp. Med. 187, 1163-1167.
273. Ottesen, S. S., Kieler, J., and Christensen, B. (1987). Changes in HLA A,B, C expression during "spontaneous" transformation of human urothelial cells in vivo. Eur. J. Cancer Clin. Oncol. 23, 991-995.
274. Pamer, E., and Cressvvell, P. (1998). Mechanisms of MHC class I-restricted antigen processing. Annii. Rev. Immiinol. 16, 323-358.
275. Pandolfi, F., Boyle, L. A., Trentin, L., Kurnick, J. T., Isselbacher, K. }., and Gattoni-Celli, S. (1991). Expression of HLA-A2 antigen in human melanoma cell lines and its role in T-cell recognition. Cancer Res. 51, 3164-3170.
276. Panelli, M. C., Wang, E., Shen, S., Schluter, S. F., Bernstein, R. M., Hersh, E. M., Stopeck, A., Gangavalli, R., Barber, J., Jolly, D., and Akporiaye, E. T. (1996). Interferon gamma (IFNgamma) gene transfer of an EMT6 tumor that is poorly responsive to IFNgamma stimulation: Increase in tumor immunogenicity is accompanied by induction of a mouse class II transactivator and class II MHC. Cancer Immiinol Imtminother. 42, 99-107.
277. Pantel, K., Schlimok, G., Kutter, D., Schaller, G., Genz, T., Wiebecke, B., Backmann, R.,Funke, L, and Riethmuller, G. (1991). Frequent down-regulation of major histocompatibil-ity class I antigen expression on individual micrometastatic carcinoma cells. Cancer Res. 51, 4712-4715.
278. Park, J. A., Wang, E., Kurt, R. A., Schluter, S. F., Hersh, E. M., and Akporiaye, E. T. (1997). Expression of an antisense transforming growth factor-betal transgene reduces tumorigenicity of EMT6 mammary tumor cells. Cancer Gene Ther. 4, 42-50.
279. Parkliurst, M. R., Fitzgerald, E. B., Southwood, S., Seite, A., Rosenberg, S.A., and Kawakami, Y. (19S8). Identification of a shared HLA-A0201-restricted T-cell epitope from the melanoma antigen Tyrosinase-related Protein (TRP2). Cancer Res. 58, 4S95-4901.
280. Passlick, B., Izbicki, J. R., Simmel, S., Kubuschok, B., arg, O., Abekost, M., better, O., Schweiberer, L., and Pentel, K. (1994). Expression of major histocompatibility class I and class II antigens and intercellular adhesion molecule-1 on operable non-small cell lung carcinomas: frequency and prognostic significance. Enr. J. Cancer 30A, 376-381.
281. Passlick, B., Pantel, K., Kubuschok, B., Angstwurm, M., Neher, A., Thetter, O., Schweiberer, L., and Izbicki, J. R. (1996). Expression of MHC molécules and ICAM-1 on non-small cell lung carcinomas: Association with early lymphatic spread of tumour cells. Eur. J. Cancer 32A, 141-145.
282. Paul, P., Rouas-Freiss, N., Khalil-Daher, I., Moreau, P., Riteau, B., Le Gai, F. A., Avril, M. F., Dausset, J., Guillet, J. G., and Carosella, E. D. (1998). HLA-G expression in melanoma: A way for tumor cells to escape from immunosurveillance. Proc. Natl. Acad. Sei. USA 95, 4510-4515.
283. Pazmany, L., Mandelboim, O., Vales-Gomez, M., Davis, D. M., Reyburn, H. T., and Strominger, J. L. (1996). Protection from natural killer cell-mediated lysis by HLA-G expression on target cells. Science 274, 792-795.
284. Pellegrino, M. A., Natali, P. G., Ng, A. K., Imai, K., Russo, A., Bigotti, A., Wolf, P., and Ferrone, S. (1982). Unorthodox expression of IA-like antigens on human tumor cells of nonlymphoid origin: Immunological properties, structural profile an clinical relevance. In Immunologie Analysis. Recent Progress in Diagnostic Laboratory Immunology, (R. M. Nakamura, W. R. Dito, and E. S. Tucker, eds.), pp. 159-173. Mason, New York.
285. Peltenburg, L. T., and Schrier, P. I. (1994). Transcriptional suppression of HLA-B expression by c-Myc is mediated through the core promoter elements. Immtmogenetics 40, 54-61.
286. Pena, J., Alonso, C., Solana, R., Serrano, R., Carracedo, J., and Ramirez, R. (1990). Natural killer susceptibility is independent of HLA class I antigen expression on cell lines obtained from human solid tumors. Eur. J. Immunol. 20, 2445-2448.
287. Pende, D., Accame, L., Pareti, L., Mazzqcchi, A., Moretta, A., Parmiani, G., and Moretta, L. (1998). The susceptibility to natural killer cell-mediated lysis of HLA class I-positive melanomas reflects the expression of insufficient amounts of different HLA class I alleles. Eur. ]. Immunol 28, 2384-2394.
288. Pende, D., Sivori, S., Accame, L., Pareti, L., Falco, M., Geraghty, D., Le Bouteiller, P., Moretta, L., and Moretta, A. (1997). IILA-G recognition by human natural killer cells. Involvement of CD94 both as inhibitory and as activating receptor complex. Eur. J. Immunol. 27, 1875-1880.
289. Peoples, G. E., Goedegebuure, P. S., Smith, R., Linehan, D. C., Yoshino, L, and Eberlein, TJ. (1995). Breast and ovarian cancer-specific cytotoxic T lymphocytes recognize the same HER2/neu-derived peptide. Proc. Natl. Acad. Sei. USA 92, 432-436.
290. Ferez, M., Cabrera, T., Lopez, N. M., Gomez, M., Peran, F., Ruiz-Cabello, F., and Garrido, F. (19S6). Heterogeneity of the expression of class I and II HLA antigens in human breast carcinoma. J. Immunogenet. 13, 247-253.
291. Perez-Villar, J. J., Melero, L, Navarro, F., Carretero, M., Bellon, T., Llano, M., Colonna, M., Geraghty, D.E., and Lopez-Botet, M. (1997). The CD94/NKG2-A inhibitory receptor complex is involved in natural killer cell-mediated recognition of cells expressing HLAGl.}. Immunol. 158, 5736-5743.
292. Peterson, L. A., Brovn, M. R., Carlisle, A. J., Kohn, E. C., Liotta, L. A., Emmert-Buck, M. R., and Krizman, D. B. (1998). An improved method for construction of directionally cloned cDNA libraries from microdissected cells. Cancer Res. 58, 5326-5328.
293. Piali, L., Weber, C., LaRosa, G., Mackay, C. R., Springer, T. A., Clark-Lewis, I., and Moser, B. (1998). The chemokine receptor CXCR3 mediates rapid and shear-resistant adhesioninduction of effector T lymphocytes by the chemokines IP10 and Mig. Eur. ]. Immunol. 28, 961-972.
294. Piancatelli, D., Romano, P., Sabastiani, P., Adomo, D., and Casciani, C. U. (1999). Local expression of cytokines in human colorectal carcinoma: evidence of specific interleukin6 gene expression. J. Imnmnother. 22, 25-32.
295. Plaksin, D., Baeuerle, P. A., and Eisenbach, L. (1993). KBF1 (p50 NF-Kappa B homodimer) acts as a repressor of H-2Kb gene expression in metastatic tumor cells. J. Exp. Med. 177, 1651-1662.
296. Plaksin, D., Gelber, C., Feldman, M., and Eisenbach, L. (19S8). Reversal of the metastatic phenotype in Lewis lung carcinoma cells after transfection with syngeneic H-2Kb gene. Proc. Natl. Acad. Sei. USA 85, 4463-4467.
297. Pockaj, B. A., Sherry, R. M., Wei, J. P., Yannelli, J. R., Carter, C. S., Leitman, S. F., Carasquillo, J. A., Steinberg, S. M., Rosenberg, S. A., and Yang, J. C. (1994). Localization of lllindium-labeled tumor infiltrating lymphocytes to tumor in patients receiving adoptive immunotherapy. Augmentation with cyclophosphamide and correlation with response. Cancer 73, 1731-1737.
298. Porgador, A., Feldman, M., and Eisenbach, L. (19S9). H-2Kb transfection of B16 melanoma cells results in reduced tumourigenicity and metastatic competence. J. Immunogenet. 16, 291-303.
299. Porgador, A., Mandelboim, O., Restifo, N. P., and Strominger, J. L. (1997a). Natural killer cell lines kill autologous betaS-microglobulin-deficient melanoma cells: implications for cancer immunotherapy. Proc. Natl. Acad. Sei. USA 94, 13140-13145.
300. Porgador, A., Yew-dell, J. W., Deng, Y., Bennink, J. R., and Germain, R. N. (1997b). Localization, quantitation, and in situ detection of specific peptide-MHC class I complexes using a monoclonal antibody. Immunity 6, 715-726.
301. Redondo, M., Concha, A., Oldiviela, R., Cueto, A., Gonzalez, A., Garrido, F., and RuizCabello, F. (1991a). Expression of HLA class I and II antigens in bronchogeniccarcinomas: its relationship to cellular DNA content and clinical-pathological parameters. Cancer Res. 51, 4948-4954.
302. Redondo, M., Ruiz-Cabello, F., Concha, A., Cabrera, T., Perez-Ayala, M., Oliva, M. R., and Garrido, F. (1991b). Altered HLA class I expression in non-small cell lung cancer is independent of c-myc activation. Cancer Res. 51, 2463-2468.
303. Rees, R. C., Buckle, A. M., Gelsthorpe, K., James, V., Potter, C. W., Rogers, K., and Jacob, G. (1988). Loss of polymorphic A and B locus HLA antigens in colon carcinoma. Br. J. Cancer 57, 374-377.
304. Reisfeld, R. A., and Cheresh, D. A. (1987). Human tumor antigens. Adv. Immunol. 40, 323-377.
305. Ressing, M. E., Sette, A., Brandt, R. M., Ruppert, J., Wentworth, P. A., Hartman, M., Oseroff, C., Grey, H. M., Melief, C. J., and Kast, W. M. (1995). Human CTL epitopes encoded by human papillomavirus type 16 E6 and E7 identified through in vivo and in vitro immunogenicity studies of HLA-A0201-bindingpeptides.y. Immunol. 154,5934-5943.
306. Restifo, N. P., Esquivel, F., Kawakami, Y., Yew-dell, J. W., Mule, J. J., Rosenberg, S. A., and Bennink, J. R. (1993). Identification of human cancers deficient in antigen processing. J. Exp. Med. 177, 265-272.
307. Restifo, N. P., Marincola, F. M., Kawakami, Y., Taubenberger, J., Yannelli, J. R., and Rosenberg, S. A. (1996a). The loss of functional b2-microglobulin in metastatic melanomas from five patients undergoing immunotherapy.J. Natl Cancer Inst. 88, 100-108.
308. Restifo, N. P., and Wunderlich, J. R. (1996b). Principles of tumor immunity: Biology of cellular immune responses. In "Biologic Therapy of Cancer," V. T. DeVita, S. Hellman, and S. A. Rosenberg, pp. 3-21. J. B. Lippincott Co., Philadelphia.
309. Ridge, J. P., Di Rosa, F., and Matzinger, P. (1998). A conditioned dendritic cell can be a temporal bridge between a CD4+ T-helper and a T-killer cell. Nature 393, 474-478.
310. Riker, A., Kammula, U. S., Panelli, M. G., Wang, E., Abati, A., Fetsch, P., Lee, K.-H., Steinberg, S. M., Rosenberg, S. A., and Marincola, F. M. (1999). Immune selection following antigen specific immunotherapy of melanoma. Surgery 126(2):112-120.
311. Rimoldi, D., Muehlethaler, K., Romero, P., Valmori, D., Hahne, M., Schneider, P., Tschopp, J., and Cerottini, J.-C. (1998). Limited involvement of the Fas/FasL pathway in melanomainduced apoptosis of tumor-specific T cells. Proc. Cancer Vacc. Week. 1, 3-82.
312. Rivoltini, L., Baracchini, K. C., Viggiano, V., Kawakami, Y., Smith, A., MLxon, A., Restifo, N. P., Topalian, S. L., Simonis, T. B., Rosenberg, S. A., and Marincola, F. M. (1995a). Quantitative correlation between HLA Class I allele expression and recognition of melanoma cells by antigen specific cytotoxic T lymphocytes. Cancer Res. 55, 3149-3157.
313. Rivoltini, L., Kawakami, Y., Sakaguchi, K., Southwood, S., Seite, A., Robbins, P. F., Marincola, F. M., Salgaller, M., Yannelli, J. R., Appella, E., and Rosenberg, S. A. (1995b). Induction of tumor reactive CTL from peripheral blood and tumor infiltrating lymphocytes of melanoma patients by in vitro stimulation with an immunodominant peptide of the human melanoma antigen MART-1. J. Immtinol. 154, 2257-2265.
314. Rivoltini, L., Loftus, D. J., Barracchini, K., Arienti, F., Mazzocchi, A., Biddison, W. E., Salgaller, M. L., Appella, E., Parmiani, G., and Marincola, F. M. (1996). Binding and presentation of peptides derived from melanoma antigens MART-1 and gplOO by HLA-A2 subtypes: Implications for peptide-based immunotherapy.J. Immunol. 156, 3882-3891.
315. Rivoltini, L., Radrizzani, M., Accomero, P., Squarcina, P., Chiodoni, C., Mazzocchi, A., Castelli, C., Tarsini, P., Viggiano, V., Belli, F., Colombo, M. P., and Parmiani, G. (1998). Human melanoma-reactive CD4+ and CD8+ CTL clones resist Fas ligand-induced apoptosis and use Fas/Fas ligand-independent mechanisms for tumor killing./ Immunol 161, 1220-1230.
316. Robbins, P. F., el-Gamil, M., Li, Y. F., Fitzgerald, E. B., Kawakami, Y., and Rosenberg, S. A. (1997). The intronic region of an incompletely spliced gp 100 gene transcript encodes an epitope recognized by melanoma-reactive tumor-infiltrating lymphocytes. ]. Immunol. 159, 303-308.
317. Robbins, P. F., el-Gamil, M., Li, Y. F., Topalian, S. L., Rivoltini, L., Sakaguchi, K., Appella, E., Kawakami, Y., and Rosenberg, S. A. (1995). Cloning of a new gene encoding an antigen recognized by melanoma-specific HLA-A24-restricted tumor-infiltrating lymphocytes. J. Immunol. 154, 5944-5950.
318. Rodeck, U., Melber, K., Kath, R., Menssen, H. D.-, Varello, M., Atkinson, B., and Herlyn, M. (1991). Constitutive expression of multiple growth factor genes by melanoma cells but not normal melanocytes. J. Invest. Dennatol. 97, 20-26.
319. Romero, P., Dunbar, P. R., Valmori, D., Pittet, M., Ogg, G. S., Rimoldi, D., Chen, J. L., Lienard, D., Cerottini, J. C., and Cerundolo, V. (1998). Ex vivo staining of metastatic lymph nodes by class I major histocompatibility complex tetramers reveals high numbers of antigen-experiencedtumor-specificcytolyticTlymphocytes.J. Exp. Med. 188,1641-1650.
320. Rosenberg, S. A. (1997). Cancer vaccines based on the identification of genes encoding cancer regression antigens. Imtnunol. Today 18, 175-182.
321. Rosenberg, S. A., Packard, B. S., Aebersold, P. M., Solomon, D., Topalian, S. L., Toy, S. T., Simon, P., Lotze, M. T., Yang, J. C., Seipp, C. A., Simpson, C., Carter, C., Block, S., Schwartzentruber, D. J., Wei, J. P., and White, D. E. (19S8). Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients vith metastatic melanoma. A preliminary report. A'. Engl. J. Med. 319, 1676-1680.
322. Rosenberg, S. A., Yang, J. C., Schwartzentruber, D., Hwu, P., Marincola, F. C., Topalian, S. L., Restifo, N. P., Dufour, E., Schwartzberg, L., Spiess, P., Wunderlich, J., Parldiurst, M. R., Kawakami, Y., Seipp, C., Einhorn, J. H., and White, D. (1998). Immunologie and therapeutic evaluation of a synthetic tumor associated peptide vaccine for the treatment of patients with metastatic melanoma. Nat. Med, 4, 321-327.
323. Rowe, M., Khanna, R., Jacob, C. A., Argaet, V., Kelly, A., Powis, S. J., Beiich, M. P., GroomCarter, D., Lee, S., Burrows, S. R., Trowsdale, J., Moss, D. J., and Rickinson, A. B. (1995). Restoration of endogenous antigen processing in Burkitt's lymphoma cells by Epstein-Barr virus latent membrane protein-1: Coordinate up-regulation of peptide transporter and HLA-class I antigen expression. Ear. J. Immunol. 25, 1374-1384.
324. Rubin, J. T., Elwood, L. J., Rosenberg, S. A., and Lotze, M. T. (19S9). Immuriohistochemical correlates of response to recombinant interleukin-2-based immunotherapy in humans. Cancer Res. 49, 70S6-7092.
325. Rubinfeld, B., Bobbins, P., el-Gamil, M., Albert, I., Porfiri, E., and Polakis, P. (1997). Stabilization of beta-catenin by genetic defects in melanoma cell lines. Science 275,1790-1792.
326. Ruiter, D. J., Bergman, W., Welvaart, K., Scheffer, E., van Violen, W. A., Russo, C., and Ferrone, S. (1984). Immunohistochemical analysis of malignant melanomas and nevocellular nevi with monoclonal antibodies to distinct monomorphic determinants of HLA antigens. Cancer Res. 44, 3930-3935.
327. Ruiter, D. J., Mattijssen, V., Broecker, E. B., and Ferrone, S. (1991). MHC antigen in human melanomas. Semin. Cancer Biol. 2(1), 35-45.
328. Ruiz-Cabello, F., Lopez, N. M., Gutierrez, J., Oliva, M. R., Romero, C., Ferron, A., Esteban, F., Huelin, C., Piris, M. A., and Rivas, C. (19S9). Phenotypic expression of histocompatibility antigens in human primary tumours and métastases. Clin. Exp. Metastasis 7,213-226.
329. Ruiz-Cabello, F., Perez-Ayala, M., Gomez, O., Redondo, M., Concha, A., Cabrera, T., and Garrido, F. (1991). Molecular analysis of MHC-class-I alterations in human tumor cell lines. Int. ]. Cancer Siippl. 6, 123-130.
330. Saas, P., Walker, P. R., Hahne, M., Quiquerez, A. L., Schnuriger, V., Perrin, G., French, L., Van Meir, E. G., de Tribolet, N., Tschopp, J., and Dietrich, P. Y. (1997). Fas ligand expression by astrocytoma in vivo: maintaining immune privilege in the brain? J. Clin. Invest. 99, 1173-1178.
331. Salazar-Onfray, F., Nakazawa, T., Chhajlani, V., Petersson, M., Karre, K., Masucci, G., Celis, E., Sette, A., Southwood, S., Appella, E., and Kiessling, R. (1997). Synthetic peptides derived from the melanocyte-stimulating hormone receptor MC1R can stimulate HLAA2-restricted cytotoxic T lymphocytes that recognize naturally processed peptides on human melanoma cells. Cancer Res. 57, 4348-4355.
332. Salgaller, M. L., Afshar, A., Marincola, F. M., Rivoltini, L., Kawakami, Y., and Rosenberg, S. A. (1995). Recognition of multiple epitopes in the human melanoma antigen gplOO by peripheral blood lymphocytes stimulated in vitro with synthetic peptides. Cancer Res. 55, 4972-4979.
333. Salgaller, M. L., Marincola, F. M., Cormier, J. N., and Rosenberg, S. A. (1996). Immunization against epitopes in the human melanoma antigen gplOO following patient immunization with synthetic peptides. Cancer Res. 56, 4749-4757.
334. Sallusto, F., and Lanzavecchia, A. (1994). Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colonystimulating factor plus interleukin 4 and downregulated by tumor necrosis factor alpha. J. Erp. Med. 179, 1109-1118.
335. Sanda, M. G., Restifo, N. P., Walsh, J. C., Kawakami, Y., Nelson, W. G., Pardoll, D., and Simons, J. W. (1995). Molecular characterization of defective antigen processing in human prostate cancer. J. Natl. Cancer Inst. 87, 280-285.
336. Scheibenbogen, C., Weyers, I., Ruiter, D., Willhauck, M., Bittinger, A., and Keilholz, U. (1996). Expression of gplOO in melanoma métastases resected before or after treatment with IFN alpha and IL-2. J. Immunother. 19, 375-380.
337. Schild, H., Rotzschke, O., Kaibacher, H., and Rammensee, H. G. (1990). Limit of T cell tolerance to self proteins by peptide presentation. Science 247, 1587-1589.
338. Schmid, P., Itin, P., and Rufli, T. (1995). In situ analysis of transforming growth factorbeta s (TGF-beta 1, TGF-beta 2, TGF-beta 3), and TGF-beta type II receptor expression in malignant melanoma. Carcinogenesis 16, 1499-1503.
339. Schmid, P., Itin, P., and Rufli, T. (1996). In situ analysis of transforming growth factorsbeta (TGF-beta 1, TGF-beta 2, TGF-beta 3) and TGF-beta type II receptor expression in basal cell carcinomas. Br. J Dennatol. 134, 1044-1051.
340. Schneider, J., Brichard, V., Boon, T., Meyer, Z. B. K., and Wolfel, T. (1998). Overlapping peptides of melanocyte differentiation antigen Melan-A/MART-1 recognized by autologous cytolytic T lymphocytes in association with HLA-B45.1 and HLA-A2.1. Int. J. Cancer 75, 451-458.
341. Schrier, P. I., and Peltenburg, L. T. (1993). Relationship between myc oncogene activation and MHC class I expression. Ado. Cancer Res. 60, 181-246.
342. Scott-Coombes, D. M., Whawell, S. A., Vipond, M. N., Cmojevic, L., and Thompson, J. N. (1993). Fibrinolytic activity of ascites caused by alcoholic cirrhosis and peritoneal malignancy. Gut 34, 1120-1122.
343. Seigier, H. F., Kremer, W. B., Metzgar, R. S., Ward, F. E., Haung, A. T., and Amos, D. B. (1971). HLA antigenic loss in malignant transformation. J. Natl. Cancer Inst. 46, 577-584.
344. Seino, K., Kayagaki, N., Okumura, K., and Yagita, H. (1997). Antitumor effect of locally produced CD95 ligand. Nat. Med. 3, 165-170.
345. Seliger, B., Hohne, A., Knuth, A., Bernhard, H., Ehring, B., Tampe, R., and Huber, C. (1996a). Reduced membrane major histocompatibility complex class I density and stability in a subset of human renal cell carcinomas with low TAP and LMP expression. Clin. Cancer Res 2, 1427-1433.
346. Seliger, B., Hohne, A., Knuth, A., Bernhard, H., Meyer, T., Tampe, R., Momburg, F., and Huber, C. (1996b). Analysis of the major histocompatibility complex class I antigen presentation machinery in normal and malignant renal cells: Evidence for deficiencies associated with transformation and progression. Cancer Res. 56, 1756-1760.
347. Seung, S., Urban, J. L., and Schreiber, II. (1993). A tumor escape variant that has lost one major histocompatibility complex class I restriction element induces specific CD8+ T cells to an antigen that no longer serves as a target.J. Ext. Med. 178, 933-940.
348. Sgadari, C., Farber, J. M., Angiolillo, A. L., Liao, F., Teruya-Feldstein, J., Burd, P. R., Yao, L., Gupta, G., Kanegane, C., and Tosato, G. (1997). Mig, the monokine induced by interferon-gamma, promotes tumor necrosis in vivo. Blood 89, 2635-2643.
349. Sharpe, J. C., Abel, P. D., Gilbertson, J. A., Brajvn, P., and Foster, C. S. (1994). Modulated expression of human leucocyte antigen class I and class II determinants in hyperplastic and malignant human prostatic epithelium. Br. J. Urol. 74, 609-616.
350. Shiraki, K., Tsuji, N., Shioda, T., Isselbacher, K. J., and Takahashi, H. (1997). Expression of Fas ligand in liver métastases of human colonie adenocarcinomas. Proc. Natl. Acad. Sei. USA 94, 6420-6425.
351. Singal, D. P., Ye, M., Ni, J., and Snider, D.P. (1996). Markedly decreased expression of TAPI and LMP2 genes in HLA class I-deficient human tumor cell lines. Immunol Lett. 50, 149-154.
352. Skipper, J. C., Kittlesen, D. J., Hendrickson, R. C., Deacon, D. D., Harthun, N. L., Wagner, S. N., Hunt, D. F., Engelhard, V. H., and Slingluff, C. L., Jr. (1996). Shared epitopes for HLA-A3-restricted melanoma-reactive human CTL include a naturally processed epitope from Pmel-17/gp100. J. Immunol. 157, 5027-5033.
353. Smith, M. E., Marsh, S. G., Bodmer, J. G., Gelsthorpe, K., and Bodmer, W. F. (1989). Loss of HLA-A, B, C allele products and lymphocyte function-associated antigen 3 in colorectal neoplasia. Proc. Natl. Acad. Sei. USA 86, 5557-5561.
354. Sogn, J. A. (1998). Tumor immunology: The glass is half full. Immunity 9, 757-763.
355. Solana, R., Romero, J., Alonso, C., and Pena, J. (1992). MHC class I antigen expression is inversely related with tumor malignancy and ras oncogene product (p21ras) levels in human breast tumors. Invasion Metastasis 12, 210-217.
356. Soong, T. W., and Hui, K. M. (1992). Locus-specific transcriptional control of HLA genes. ]. Immunol. 149, 2008-2020.
357. Spom, M. B., and Roberts, A. B. (1992). Transforming growth factor-beta: recent progress and new challenges.J. Cell. Biol 119, 1017-1021.
358. Stevens, E. J., Jacknin, L., Robbins, P. F., Kawakami, Y., el Gamil, M., Rosenberg, S. A., and Yannelli, J. R. (1995). Generation of tumor-specific CTLs from melanoma patients by using peripheral blood stimulated with allogeneic melanoma tumor cell lines. Fine specificity and MART-1 melanoma antigen recognition. J. Immunol. 154, 762-771.
359. Strand, S., Hofmann, W.J., Hug, H., Muller, M., Otto, G., Strand, D., Mariani, S. M., Stremmel, W., Krammer, P.H., and Galle, P. R. (1996). Lymphocyte apoptosis induced by CD95 (APO-I/Fas) ligand-expressing tumor cells-A mechanism of immune evasion? Nat. Med. 2, 1361-1366.
360. Sykulev, Y., Joo, M., Vturina, I., Tsomides, T. J., and Eisen, H. N. (1996). Evidence that a single peptide-MHC complex on a target cell can elicit a cytolytic T cell response. Immunity 4, 565-571.
361. Taga, K., and Tosato, G. (1992). IL-10 inhibits human T cell proliferation and IL-2 production.J. Immunol. 148, 1143-1148.
362. Takata, M., Hirone, T., and Matsumura, H. (1989). Beta 2 microglobulin expression in normal melanocytes, nevocellular nevi, and malignant melanomas. J. Invest. Dennatol. 92, 243S-247S.
363. Tanaka, Y., Anderson, R. W., Maloy, W. L., and Tevethia, S. S. (1989). Localization of an immunorecessive epitope on SV40 T antigen by H-2Db-restricted cytotoxic T-Iymphocyte clones and a synthetic peptide. Virology 171, 205-213.
364. Tanaka, K., Isselbacher, K. J., Khoury, G., and Jay, G. (1985). Reversal of oncogenesis by the expression of a major histocompatibility complex class I gene. Science 228, 26-30.
365. Tanaka, Y., Tevethia, M. J., Kalderon, D., Smith, A. E., and Tevethia, S. S. (1988). Clustering of antigenic sites recognized by cytotoxic T lymphocyte clones in the amino terminal half of SV40 T antigen. Virofogi/ 162, 427-436.
366. Temponi, M., Romano, G., D'Urso, G. M., Wang, Z., Kekish, V., and Ferrone, S. (1988). Profile of intercellular adhesion molecule-1 (ICAM-1) synthesized by human melanoma cell lines. Semin. Oncol. 15, 595-607.
367. Tensen, C.P., Vermeer, M. H., van der Stoop, P. M., van Beek, P., Scheper, R. J., Boorsma, D. M., and Willemze, R. (1998). Epidermal interferon-gamma inducible protein-10 (IP-10) and monokine induced by gamma-interferon (Mig) but not IL-8 mRNA expression is associated with epidermotropism in cutaneous T cell lymphomas. J. Invest. Dennatol. Ill, 222-226.
368. Terol, M. J., Lopez-Guillermo, A., Bosch, F., Villamor, N., Cid, M. G., Rozman, C., Campo, E., and Monstserrat, E. (1998). Expression of the adhesion molecule ICAM-1 in nonHodgkin's lymphoma: relationship with tumor dissemination and prognostic importance. J. Clin. Oncol. 16, 35-40.
369. Tevethia, S. S. (1990). Recognition of simian virus 40 T antigen by cytotoxic T lymphocytes. Mol. biol. Ued. 7, 83-96.
370. Thomas, L. (1959). "Cellular and Humoral Aspects of the Hypesensitive State." Hoeber, New York.
371. Toes, R. E., Blom, R. J., Offringa, R., Kast, W. M., and Melief, C. J. (1996a). Enhanced tumor outgrowth after peptide vaccination. Functional deletion of tumor-specific CTL induced by peptide vaccination can lead to the inability to reject tumors. J. Immunol. 156, 3911-3918.
372. Toes, R. E., Offringa, R., Blom, R. J., Melief, C. J., and Kast, W. M. (1996b). Peptide vaccination can lead to enhanced tumor growth through specific T-cell tolerance induction. Proc. Natl. Acad. Sei. USA 93, 7855-7860.
373. Toes, R. E., Schoenberger, S. P., van der Voort, E. I., Kast, W. M., Hoeben, R. C., Melief, C. J., and Offringa, R. (1997). Activation or frustration of anti-tumor responses by T-cellbased immune modulation. Semin. Immunol. 9, 323-327.
374. Tomita, Y., Matsumoto, Y., Nishiyama, T., and Fujiwara, M. (1990a). Reduction of major histocompatibility complex class I antigens on invasive and high-grade transitional cell carcinoma. J. Pathol. 162, 157-164.
375. Tomita, Y., Nishiyama, T., Fujiwara, M., and Sato, S. (1990b). Immunohistochemical detection of major histocompatibility complex antigens and quantitative analysis of tumourinfiltrating mononuclear cells in renal cell cancer. Br. J. Cancer 62, 354-359.
376. Topalian, S. L., Rivoltini, L., Mancini, M., Markus, N. R., Robbins, P. F., Kawakami, Y., and Rosenberg, S. A. (1994). Human CD4+ T cells specifically recognize a shared melanoma-associated antigen encoded by the tyrosinase gene. Proc. Natl. Acad. Sei. USA 91, 9461-9465.
377. Torres, L. M., Cabrera, T., Concha, A., Oliva, M. R., Ruiz-Cabello, F., and Garrido, F. (1993). HLA class I expression in HPV-16 sequences in premalignant and malignant lesions of the cerivix. Tissue Antigens 41, 65-71.
378. Torres, M. J., Ruiz-Cabello, F., Skoudy, A:, Berrozpe, G., Jimenez, P., Serrano, A., Real, F. X., and Garrido, F. (1996). Loss of an HLA haplotype in pancreas cancer tissue and its corresponding tumor derived cell line. Tissue Antigens 47, 372-381.
379. Tsang, K. Y., Zaremba, S., Nieroda, C. A., Zhu, M. Z., Hamilton, J. M., and Schlom, J. (1995). Generation of human cytotoxic T cells specific for human carcinoembryonic antigen epitopes from patients immunized with recombinant vaccinia-CEA vaccine. J. Natl. Cancer Inst. 87, 982-990.
380. Urban, J. L., Kripke, M. L., and Schreiber, H. (1986) Stepwise immunologie selection of antigenic variants during tumor growth. J. Immunol. 137, 3036-3041.
381. Urban, J.L., Van Waes, C., and Schreiber, H. (1984). Pecking order among tumor-specific antigens. Eur. J. Immunol. 14, 181-187.
382. Uyttenhove, C., Maryanski, J., and Boon, T. (1983). Escape of mouse mastocytoma P815 after nearly complete rejection is due to antigen-loss variants rallier than immunosuppression. J. Exp. Med. 157, 1040-1052.
383. Valitutti, S., Muller, S., Cella, M., Padovan, E., and Lanzavecchia, A. (1995). Serial triggering of many T-cell receptors by a few peptide-MHC complexes. Nature 375, 148-151.
384. Valitutti, S., Muller, S., Dessing, M., and Lanzavecchia, A. (1996). Different responses are elicited in cytotoxic T lymphocytes by different levels of T cell receptor occupancy. J. Exp. Med. 183, 1917-1921.
385. Van't Veer, L. J., Beijersbergen, R. L. and Bernards, R. (1993) N-myc suppresses major histocompatibility complex class I gene expression through down-regulation of the p50 subunit of NF-kappa. EMBO J. 12, 195-202.
386. Van Belle, P., Rodeck, U., Nuamah, I., Halpern, A. C., and Elder, D. E. (1996). Melanomaassociated expression of transforming growth factor-beta isoforms. Am. J. Pathol. 148, 1887-1894.
387. Van den Eynde, B., Lethe, B., Van Pel, A., De Plaen, E., and Boon, T. (1991). The gene coding for a major tumor rejection antigen of tumor P815 is identical to the normal gene of syngeneic DBA/2 mice. J. Exp. Med. 173, 1373-1384.
388. Van den Eynde, B., Peelers, O., De Backer, O., Gaugler, B., Lucas, S., and Boon, T. (1995). A new family of genes coding for an antigen recognized by autologous cytolytic T lymphocytes on a human melanoma. J. Exp. Med. 182, 689-698.
389. van den Ingh, H. F., Ruiter, D. J., Griffioen, G., van Muijen, G. N., and Ferrone, S. (19S7). HLA antigens in colorectal tumours-low expression of HLA class I antigens in mucinous colorectal carcinomas. Br. J. Cancer 55, 125-130.
390. van der Bruggen, P., Bastin, J., Gajewski, T., Coulie, P. G., Boel, P., De Smet, C., Traversari, C., Townsend, A., and Boon, T. (1994a) A peptide encoded by human gene MAGE-3 and presented by HLA-A2 induces cytolytic T lymphocytes that recognize tumor cells expressing MAGE-3. Eur. J. Immunol. 24, 3038-3043.
391. van der Bruggen, P., Szikora, J. P., Boel, P., Wildmann, C., Somville, M., Sensi, M., and Boon, T. (1994b). Autologous cytolytic T lymphocytes recognize a MAGE-1 nonapeptide on melanomas expressing HLA-Cw1601. Eur. J. Immunol. 24, 2134-2140.
392. van der Bruggen, P., Traversari, C., Chômez, P., Lurquin, C., De Plaen, E., Van den Eynde, B., Knuth, A., and Boon, T. (1991). A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science 254, 1643-1647.
393. van der Burg, S. H., Visseren, M. J., Brandt, R. M., Kast, W. M., and Melief, C. J. (1996). Immunogenicity of peptides bound to MHC class I molecules depends on the MHCpeptide complex stability. J. Immunol. 156, 3308-3314.
394. van Driel, W. J., Tjiong, M. Y., Hilders, C. G., Trimbos, B. J., and Fleuren, G. J. (1996). Association of allele-specific HLA expression and histopathologic progression of cervical carcinoma. Gynecol. Oncol. 62, 33-41.
395. van Duinen, S. G., Ruiter, D. J., Broecker, E. B., van der Velde, E. A., Sorg, C., Welvaart, K., and Ferrone, S. (1988). Level of HLA antigens in locoregional métastases and clinical course of the disease in patients with melanoma. Cancer Res. 48, 1019-1025.
396. van Parijs, L., and Abbas, A. K. (1998). Homeostasis and self-tolerance in the immune system: turning lymphocytes off. Science 280, 243-248.
397. van Waes, C., Monach, P. A., Urban, J. L., Wortzel, R. D., and Schreiber, H. (1996). Immunodominance deters the response to other tumor antigens thereby favoring escape: Prevention by vaccination with tumor variants selected with cloned cytolytic T cells in vitro. Tissue Antigens 47, 399-407.
398. Vanky, F., Wang, P., Patarroyo, M., and Klein, E. (1990). Expression of the adhesion molecule ICAM-1 and major histocompatibility complex class I antigens on human tumor cells is required for their interaction with autologous lymphocytes in vitro. Cancer Immunol. Immun. 31, 19-27.
399. Vennegoor, C., Calafat, J., Hageman, P., van Buitenen, F., Janssen, H., Kolk, A., and Rumke, P. (1985). Biochemical characterization and cellular localization of a formalin-resistant melanoma-associated antigen reacting with monoclonal antibody NKI/C-3. Int. J. Cancer 35, 287-295.
400. Vennegoor, C., Hageman, P., Van Nouhuijs, H., Ruiter, D. J., Calafat, J., Ringens, P.J., and Rumke, P. (1988). A monoclonal antibody specific for cells of the melanocyte lineage. Am. J. Pathol 130, 179-192.
401. Versteeg, R., Kruse-Wolters, K. M., Plomp, A. C., van Leeuwen, A., Stam, N. J., Ploegh, II. L., Ruiter, D. J., and Schrier, P. I. ( 19S9a) Suppression of class I human histocompatibility leukocyte antigen by c-myc is locus specific. J. Exp. Med. 170, 621-635.
402. Versteeg, R., Noordermeer, I. A., Kruse-Wolters, M., Ruiter, D. J., and Schrier, P. I. (1988). c-myc down-regulates class I HLA expression in human melanomas. EMBO J. 7, 1023-1029.
403. Versteeg, R., Peltenburg, L. T., Plomp, A. C., and Schrier, P. I. (1959b). High expression of the c-myc oncogene renders melanoma cells prone to lysis by natural killer cells. J. Immunol 143, 4331-4337.
404. Vieira, P., de Waal-Malefyt, R., Dang, M. N., Johnson, K. E., Kastelein, R., Fiorentino, D. F., deVries, J. E., Roncarolo, M. G., Mosmann, T. R., and Moore, K. W. (1991). Isolation and expression of human cytokine synthesis inhibitory factor cDNA clones: homology to Epstein-Barr virus open reading frame BCRFI. Troc. Natl. Acad. Sei. USA 88, 1172-1176.
405. Viola, A., and Lanzavecchia, A. (1996). T cell activation determined by T cell receptor number and tunable thresholds. Science 273, 104-106.
406. Visseren, M. J. W., van Elsas, A., van der Voort, E. I. H., Ressing, M. A., Käst, W. M., Schrier, P. L, and Melief, J. M. (1995). CTL specific for the tyrosinase autoantigen can be induced from healthy donor blood to lyse melanoma cells.J. Immunol. 154,3991-3998.
407. Vitale, M., Rezzani, R., Rodella, L., Zauli, G., Grigolato, P., Cadei, M., Hicklin, D. J., and Ferrone, S. (1998). HLA class I antigen and transporter associated with antigen processing (TAPI and TAP2) down-regulation in high-grade primary breast carcinoma lesions. Cancer Res. 58, 737-742.
408. Vitale, M. J. W., van Elsas, A., van der Voort, E. I. IL, Ressing, M. A., Käst, W. M., Schrier, P. L, and Melief, J. M. (1995). CTL specific for the tyrosinase autoantigen can be induced from healthy donor blood to lyse melanoma cells. J. Immunol. 154, 3991-3998.
409. Vitiello, A., Ishioka, G., Grey, II. M., Rose, R., Farness, P., LaFond, R., Yuan, L., Chisari, F. V., Furze, J., Bartholomeuz, R., and Chesnut, R. W. (1995). Development of a lipopeptide-based therapeutic vaccine to treat chronic HBV infection. I. Induction of a primary cytotoxic T lymphocyte response in humans.J. Clin. Invest. 95, 341-349.
410. von Mehren, M., and Weiner, L. M. (1996). Monoclonal antibody-based therapy. Curr. Opin. Oncol. 8, 493-498.
411. Vora, A. R., Rodgers, S., Parker, A. J., Start, R., Rees, R. C., and Murray, A. K. (1997). An immunohistochemical study of altered immunomodulatory molecule expression in head and neck squamous cell carcinoma. Br. J. Cancer 76, 836-844.
412. Wakefield, L. M., Letterio, J. ]., Geiser, A. G., Flanders, K. C., O'Shaughnessy, J., Roberts, A. B., and Sporn, M. B. (1995). Transforming growth factor-beta s in mammary tumorigenesis: promoters or antipromoters? Prog. Clin. Biol. Res. 391, 133-148.
413. Wallich, R., Bulbuc, N., Hammerling, G. J., Katzav, S., Segal, S., and Feldman, M. (1985). Abrogation of metastatic properties of tumour cells by de novo expression of H-2K antigens following II-2 gene transfection. Nature 315, 301-305.
414. Wang, C. Y., Mayo, M. W., and Baldwin, A. S. J. (1996a). TNF-a and cancer therapyinduced apoptosis: potentiation by inhibition of NF-kappaB. Science 274, 784-787.
415. Wang, R. F., Appella, E., Kawakami, Y., Kang, X., and Rosenberg, S. A. (1996b). Identification of TRP-2 äs a human tumor antigen recognized by cytotoxic T lymphocytes.J. Exp. Med. 184, 2207-2216.
416. Wang, R. F., Johnston, S. L., Zeng, G., Topalian, S. L., Schwartzentruber, D. J., and Rosenberg, S. A. (1998). A breast and melanoma-shared tumor antigen: T cell responses to antigenic peptides translated from different open reading frames. J. Immunol. 161, 3598-3606.
417. Wang, R. F., Parkhurst, M. R., Kawakami, Y., Robbins, P. F., and Rosenberg, S. A. (1996). Utilization of an alternative open reading frame of a normal gene in generating a novel human cancer antigen.J. Exp. Med. 183, 1131-1140.
418. Wang, Z., Cao, Y., Albino, A. P., Zeff, R. A., Houghton, A., and Ferrone, S. (1993). Lack of HLA class I antigen expression by melanoma cells SK-MEL- 33 caused by a reading frameshift in beta 2-microglobulin messenger RNA.J. Clin. Invest. 91, 684-692.
419. Wang, Z., Margulies, L., Hicklin, D. J., and Ferrone, S. (1996). Molecular and functional phenotypes of melanoma cells with abnormalities in HLA class I antigen expression. Tissue Antigens 47, 382-390.
420. Wang, Z., Marincola, F. M., Rivoltini, L., Parmiani, G., and Ferrone, S. (1999). Sélective histocompatibility leukocyte antigen (HLA)-A2 loss caused by aberrant pre-mRNA splicing in 624MEL28 melanoma cells.J. Exp. Med. 190(2):205-215.
421. Webb, D. S., Mostowski, H. S., and Gerrard, T. L. (1991). Cytokine-induced enhancement of ICAM-1 expression results in increased vulnerability of tumor cells to monocyte-mediated lysis. J. Immunol. 146, 3682-3686.
422. Weber, J., Salgaller, M., Samid, D., Johnson, B., Ilerlyn, M., Lassam, N., Treisman, J., and Rosenberg, S. A. (1994). Expression of the MAGE-1 tumor antigen is up-regulated by the demethylating agent 5-aza-2'-deoxycytidine. Cancer Res. 54, 1766-1771.
423. Wei, M. L., and Cresswell, P. (1992). HLA-A2 molecules in an antigen-processing mutant cell contain signal sequence-derived peptides. Nature 356, 443-446.
424. Wettstein, P. J., and Bailey, D. W. (1982). Immunodominance in the immune response to "multiple" histocompatibility antigens. Immunogenetics 16, 47-58.
425. White, R. L. (1998). Excess risk of colon cancer associated with a polymorphism of the APC gene? Cancer Res. 58, 4038-4039.
426. Whitwell, H. L., Hughes, H. P., Moore, M., and Ahmed, A. (1984). Expression of major histocompatibility antigens and leucocyte infiltration in benign and malignant human breast disease. Br. J. Cancer 49, 161-172.
427. Wimmenauer, S., Keller, H., Ruckauer, K. D., Rahner, S., Wolff-Vorbeck, G., Kirste, G., von Kleist, S., and Farthman, E. H. (1997). Expression of CD44, ICAM-1 and N-CAM in colorectal cancer. Correlation with the tumor stage and the phenotypical characteristics of tumor-infiltrating lymphocytes. Anticancer Res. 17, 2395-2400.
428. Wintzer, H. O., Benzing, M., and von Kleist, S. (1990) Lacking prognostic significance of beta 2-microglobulin, MHC class I and class II antigen expression in breast carcinomas. Br. J. Cancer 62, 289-295.
429. Wojtowicz-Praga, S. (1997). Reversal of tumor-induced immunosuppression: a new approach to cancer therapy. J. Immunother. 20, 165-177.
430. Wojtowicz-Praga, S., Verma, U. N., Wakefield, L., Esteban, J. M., Hartmann, D., Mazumder, A. andVerma, U. M. (1996). Modulation of B16 melanoma growth and metastasis by anti-transforming growth factor beta antibody and interleukin-2.J. Immunother. 19,169-175.
431. Wolf, J. E., Faanes, R. B., and Choi, Y. S. (1977). Antigenic changes of DBA/2J mastocytoma cells when grown in the BALB/c mouse. J. Natl. Cancer Inst. 58, 1407-1412.
432. Wolfel, T., Hauer, M., Schneider, J., Serrano, M., Wolfel, C., Klehmann-Hieb, E., De Plaen, E., Hankein, T., Meyer, z. B. K., and Beach, D. (1995). A p16INK4a-insensitive CDK4 mutant targeted by cytolytic T lymphocytes in a human melanoma. Science 269, 1281-1284.
433. Wolfel, T., Klehmann, E., Muller, C., Schutt, K.H., Meyer zum Buschenfelde, K. H., and Knuth, A. (1989a). Lysis of human melanoma cells by autologous cytolytic T cell clones. Identification of human histocompatibility leukocyte antigen A2 as a restriction element for three different antigens. J Exp Med 170, 797-810.
434. Wolfel, T., Van Pel, A., Brichard, V., Schneider, J., Seliger, B., Meyer zum Buschenfelde, K. H. and Boon, T. (1994). Two tyrosinase nonapeptides recognized on HLA-A2 melanomas by autologous cytolytic T lymphocytes. Eur. J. Immunol. 24, 759-764.
435. Wu, P. C., Alexander, H. R., Huang, J., Hwu, P., Gnant, M. F., Berger, A., Turner, E., Wilson, O., and Libutti, S. K. (1998). In vivo sensitivity of human melanoma to tumor necrosis factor (TNF)-a is determined by tumor production of the novel cytokine endothelial-monocyte activating polypeptide II (EMAII). Cancer Res. 59(1):205-212.
436. Wucherpfennig, K. W., and Strominger, J. L. (1995). Molecular mimicry in T cell-mediated autoimmunity: Viral peptides activate human T cell clones specific for myelin basic protein. Cell 80, 695-705.
437. Yewdell, J. W., and Bennink, J. R. (1990). The binary logic of antigen processing and presentation to T cells. Cell 62, 203-206.
438. Yoong, K. F., McNab, G., Hubscher, S. G., and Adams, D. H. (1998). Vascular adhesion protein-1 and ICAM-1 support the adhesion of tumor-infiltrating lymphocytes to tumor endothelium in human hepatocellular carcinoma. J. Immunol. 160, 3978-3988.
439. York, I. A., and Rock, K. L. (1996). Antigen processing and presentation by the class I major histocompatibility complex. Anna. Rev. Immunol. 14, 369-396.
440. Yoshino, I., Peoples, G. E., Goedegebuure, P. S., Maziarz, R., and Eberlein, T.J. (1994). Association of HER2/neu expression with sensitivity to tumor-specific CTL in human ovarian cancer. ]. Immunol. 152, 2393-2400.
441. Yue, F.Y., Dummer, R., Geertsen, R., Hofbauer, G., Laine, E., Manolio, S., and Burg, G. (1997). Interleukin-10 is a growth factor for human melanoma cells and down-regulates HLA class-I, HLA class-II and ICAM-1 molecules. Int. ]. Cancer 71, 630-637.
442. Zajac, A. J., Blattman, J. N., Murali-Krishna, K., Sourdive, D. J. D., Suresh, M., Altman, J. D., and Ahmed, R. (1998). Viral immune evasion due to persistence of activated T cells without effector function.J. Exp. Med. 188, 2205-2213.
443. Zaks, T. Z., Chappell, D. B., Rosenberg, S. A., and Restifo, N. P. (1999). Fas-mediated suicide of tumor-reactive T cells following activation by specific tumor: Selective rescue by Caspase inhinition. J. Immunol. 162(6):3273-3279.
444. Zea, A. H., Curti, B. D., Longo, D. L., Alvord, W. G., Strobl, S. L., Mizoguchi, H., Creekmore, S. P., O'Shea, J. J., Powers, G. C., Urba, W. J., and Ochoa, A. C. (1995). Alterations in T cell receptor and signal transduction molecules in melanoma patients. Clin. Cancer Res. 1, 1327-1335.
445. Zuk, J. A., and Walker, R. A. (1987). Immunohistochemical analysis of HLA antigens and mononuclear infiltrates of benign and malignant breast. J. Patliol. 152, 275-285.